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ABSTRACT
“Burden of Breast Cancer and Associated Health and Economic Outcomes in Elderly
Women in West Virginia: Comparison with National Estimates”
Ami Maulik Vyas

West Virginia (WV) which is the only state which lies entirely in Appalachia and which
is predominantly rural and medically underserved region, has lower incidence of breast cancer
(BC) but a higher BC-related mortality as compared to the national averages in elderly women
age 65 and above. This may be due to lower mammography utilization in these rural elderly
women, limited physical access to services, shortage of healthcare professionals and services,
and untimely and/or inappropriate care. This is dearth of epidemiological studies that have
focused on understanding the factors associated with these disparities among these rural and
underserved population such as WV. The purpose of this project was to do a detailed evaluation
of burden of BC and its associated health and economic outcomes in elderly women in WV, and
to compare these estimates with the national estimates. Three retrospective observational studies
were conducted using West Virginia Cancer Registry-Medicare and Surveillance, Epidemiology,
and End Results (SEER)-Medicare linked datasets for the years 2002-2007. In the first study,
persistence with mammography screening and its effect on stage at BC diagnosis was
investigated for the elderly rural WV women and was compared to the national estimates from
SEER-Medicare data. The study found no significant differences in the representation of disease
between WV-Medicare and SEER-Medicare cohorts even after controlling for persistence with
mammography screening. In the second study, timeliness of BC care in regards to diagnosis and
treatment as per the published opinion-based recommendations and its effect on chances of being
alive at the follow-up period was determined for the WV-Medicare cohort and then was
compared to the SEER-Medicare cohort. The study found that the WV-Medicare cohort was
significantly less likely to receive timely diagnosis of BC as per recommendations when
compared to the SEER-Medicare cohort. However, there were no significant differences
between these cohorts for the timely treatment of BC. Also, delayed diagnosis was not
associated with poorer prognosis in the WV-Medicare cohort. In the third study, average total
healthcare costs in the initial phase of 12-months following BC diagnosis and costs by types of
specific services were estimated for the WV-Medicare cohort and these were compared to the
national estimates derived from the SEER-Medicare cohort. This study reported that average
total healthcare costs, inpatient costs and physician services costs were significantly lower for the
WV-Medicare cohort as compared to the SEER-Medicare cohort. Also, the decomposition
analyses only explained total 16% of the differences in the average costs due to the cohorts’
characteristics. Overall, the findings of this project highlight the importance of persistence with
mammography screening and timely BC care in the elderly, rural and underserved women
diagnosed with BC. Moreover, these studies can serve as a foundation for larger studies aimed at
decreasing BC disparities in a rural and geographically challenged state such as WV, through the
development of strategies and interventions to foster early detection and timely treatment of BC
among rural populations.
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CHAPTER 1
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CHAPTER 1
INTRODUCTION
BACKGROUND
Breast Cancer Overview
Breast cancer (BC) is a malignant tumor that starts in the cells of the breast. A malignant
tumor is a group of cancer cells that invade surrounding tissues of the breast or metastasize to
distant areas of the body. BC is the most common cancer in women and is the second leading
cause of cancer death in women in the United States (US). About 1 in 8 (12%) women in the US
will develop invasive BC during their lifetime. According to the 2014 statistics by American
Cancer Society, it is estimated that about 232,670 new cases of invasive BC, and about 62,570
new cases of carcinoma in situ (CIS) will be diagnosed, and 40,000 women will die from BC in
the US 1.
Risk factors for Breast Cancer 2
There are various modifiable and non-modifiable factors which affect a woman’s chance
of developing BC. Some of the non-modifiable risk factors increasing a woman’s risk of
developing BC are gender (female), advanced age, family history of BC, personal history of BC,
early menarche and late menopause, inherited genetic mutations (BRCA1/BRCA2 or others),
having dense breast tissue, some benign breast conditions, previous chest radiation for other
malignancies, and diethylstilbestrol exposure. Modifiable risk factors associated with the
development of BC in women include nulliparity, delayed child bearing, no full-term
pregnancies, never breastfed, oral contraceptive use, post-menopausal hormone therapy, obesity,
decreased physical activity, and alcohol consumption.
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Breast Cancer Epidemiology
BC incidence and mortality rates vary significantly by age. Based on 2005-2009
Surveillance, Epidemiology and End Results (SEER) statistics, the median age at diagnosis and
mortality due to BC is 61 and 68 years, respectively 3. Also, 41% of the new BC cases and
57.4% of the BC deaths occur in women age 65 and above 3. The overall incidence of BC in
women below 65 years of age is 82.97 per 100,000 and is 421.30 per 100,000 women in those
above age 65 3. The overall mortality from BC is 11.15 per 100,000 women for those less than
65 years of age and is 98.64 per 100,000 women in those above age 65 3. Furthermore, older
women age 65 and above have a greater burden of BC as they are diagnosed at advanced stages
and with larger tumors impacting their survival 4.
Mammography Screening
Screening tests can find cancers in early stages before they start to cause symptoms and
hence help in reducing cancer-related mortality. Mammography screening is considered to be
the ‘gold standard’ for women at average risk and it enables BC detection at an early stage, when
the treatment is most effective and tends to require less intense systemic and local therapies 5,6.
Several clinical trials have shown that mammography screening reduces BC-related mortality by
20-35% in women age 40-69 years of age 6-10. Also, a recent Cochrane review reported that
mammography screening reduces relative risk in BC mortality by 15% with 0.05% reduction in
absolute risk 11.
Women diagnosed with BC who have had a screening mammogram within the previous
two years are significantly less likely to have late-stage disease 12. However, in 2010, only 64%
of women age 65 and above had a mammography screening within the previous two years as
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compared to 73% of women age 50-64 years 2 even though annual screening mammograms are
recommended and covered by both Medicare and Medicaid.
Breast Cancer and Mammography Screening in West Virginia
West Virginia (WV) is the only state that lies entirely in Appalachia, a region which is
predominantly rural and medically underserved, characterized by high poverty rates, low levels
of education, an aging population, high rates of chronic disease, and poor health behaviors 13-16.
For 2009, WV was reported to have a lower incidence of BC (112.6 vs. 122.9 nationally) but a
higher BC-related mortality (23.3 vs. 22.2 nationally) 17,18. Also, WV is reported to have higher
rates of advanced and unstaged BC 19-23, which has been attributed to lower mammography
screening rates of women in WV 20-24. In 2010, WV was ranked 48th among US states for
women having mammography screening within the past two years 25. In 2008, WV was ranked
sixth nationally in BC deaths 26,27.
In WV women age 65 years and above, BC accounted for 12% of all the incident cancer
cases 28 and 5.3% of all cancer deaths 29. For 2009 among women age 65 and older, WV had
lower incidence of BC (372.8 per 100,000 vs. 411.7 per 100,000) but higher BC-related
mortality (110.4 per 100,000 vs. 98.6 per 100,000) 17,18 as compared to the national estimates.
This may be attributed to numerous factors such as lower mammography screening rates in these
elderly women 21-23,30, limited physical access to services, shortage of healthcare professionals
and services 31, and untimely BC care. These disparities also indicate that elderly women
diagnosed with BC in WV may have higher healthcare costs after cancer diagnosis.
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NEED FOR STUDY
Persistence with Mammography Screening and Stage at Breast Cancer Diagnosis
Though mammography screening has been shown to reduce BC mortality by 20-35% in
the average-risk women age 40-69 years 6-10, it is not clearly evident whether or not
mammography screening is beneficial in older women. This is because very few screening trials
assessing the benefits of mammography screening have included women aged 70 and above 32.
Moreover, there is a deficit of evidence-based guidelines for mammography screening in elderly
women. Current US-based guidelines about screening mammography 33-35 have no upper age
limit set for the procedure and suggest woman should have mammography screening as long as
she is in good health. Elderly women age 65 and above have a greater burden of BC as cancer
tends to be found at advanced stages with larger tumor sizes, and thereby leading to poorer
survival 4. Additionally, the literature has also reported that these women are less likely to utilize
mammography screening as compared to their younger counterparts 33,36,37. In 2010, 64% of
women age 65 and above had a mammography screening within the previous two years as
compared to 73% among women age 50-64 years 33. Various studies have demonstrated the
benefits of mammography screening utilization in women age 65 and above on stage at BC
diagnosis, an important predictor of survival 38-41. Yet, these studies have limitations in terms of
only including younger women, utilizing data from fewer cancer registries or utilizing data from
limited time period before BC diagnosis, and not effectively distinguishing screening and
diagnostic mammography claims, an inherent problem with Medicare claims data.
Very limited information is available about the effect of mammography screening and
stage at BC diagnosis among elderly Medicare beneficiaries diagnosed with BC from rural
settings and non-SEER Medicare states. With lower incidence of BC but higher BC-related
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mortality in elderly WV women and lower mammography screening rates in these women, there
is a vital need to determine the association between persistence with mammography screening
and stage at BC diagnosis.
Timeliness of Care among Elderly Women Diagnosed with Breast Cancer
Though BC is a major health issue and the second cause of cancer-related deaths in
women in the US, measuring quality of care delivered to women diagnosed with BC is extremely
challenging. Timeliness of care i.e. prompt diagnosis after detecting an abnormality in the breast
and prompt initiation of the treatment after BC diagnosis is an important component of highquality BC treatment. Providing timely care to BC patients is significant to both patients and
primary providers in order to reduce BC-related mortality 42,43. Despite the widely accepted
benefit of timely care in BC patients, the US-based guidelines have yet to define an appropriate
time frame from presentation of abnormality in a breast to confirmed BC diagnosis and from BC
diagnosis to the initiation of the treatment. However, other international oncology organizations
such as European Society of Breast Cancer Specialists (EUSOMA) and National Health Service
of United Kingdom have published professional opinion-based recommendations. Each group
provides recommendations on time intervals between events such as presentation of abnormality
to diagnosis of BC 44 and between BC diagnosis to the initiation of the treatment 45, respectively.
Various studies regarding timeliness of BC care have been conducted in the last decade in
the US 46-54, but no consensus exists regarding an appropriate time from diagnosis and to
treatment. Also, none of these studies have followed any published opinion-based
recommendations to appropriately define timely diagnosis and treatment.
As elderly women age 65 years and above have higher BC incidence and mortality and
are more likely to have advanced stage disease at diagnosis 3,4, it is highly likely that delayed
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diagnosis and/or delayed treatment may negatively affect the prognosis of the disease, and hence
their survival. Previous literature has also reported that delay in diagnosis is a major factor
contributing to the poor survival in elderly women diagnosed with BC 4. Hence, it is
exceedingly important to determine timeliness of BC care based on the published opinion-based
recommendations among elderly women with BC in the US. In addition, as WV had a lower
incidence of BC among women age 65 and above but higher BC-related mortality 17,18 as
compared to the national estimates, it is possible that the timeliness of care may be one of the
important contributors to these disparities. Therefore, a study comparing the timeliness of BC
care among elderly WV women diagnosed with BC to the national estimates may help begin to
understand these disparities.
Total Healthcare Costs of Breast Cancer in the Initial Phase (12-months) After Diagnosis
The lifetime per-patient direct medical care cost estimates of BC ranged from $20,000 to
$100,000 for the base cost year from 1984 to 2003 55. The direct medical costs of initial and
terminal care for women with BC are reported to be significantly higher than that of the
continuing care on a per unit time basis 55. This is because the costs of BC care are substantial
during the initial care (12-months) period encompassing the time from diagnosis to surgery,
radiation and adjuvant systemic therapy which constitute the major cost components in cancer
therapy 56-59.
To date, a majority of the studies estimating total healthcare costs during the initial period
after BC diagnosis in elderly women are either outdated or have utilized SEER-Medicare data
from fewer cancer registries and states/regions or have not stratified the results by stage at
diagnosis, comorbidity and type of initial treatment. Besides, very limited information is
available about the healthcare costs in elderly women diagnosed with BC from rural settings and
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from non-SEER states, such as WV. As WV has a lower incidence of BC but a higher BCrelated mortality among women age 65 and older 17,18 as compared to the national estimates and
with the increasing median age of the population and higher BC cases at advanced stages, it may
be likely that healthcare costs during the initial period among elderly WV women diagnosed with
BC may be higher as compared to the national estimates. Thus, a study comparing the healthcare
costs during the initial period of 12-months among elderly WV women diagnosed with BC with
that of the national estimates is essential to understand any such disparities. This data may aid in
planning for healthcare costs and may facilitate resource allocation in the future.
SPECIFIC AIMS AND OBJECTIVES
The specific aims and objectives of the project are:
Specific Aim 1: To determine the association between persistence with mammography
screening and stage at BC diagnosis among Medicare fee-for-service (FFS) beneficiaries in WV
and compare it with national estimates from the SEER-Medicare data
Objective 1: To determine the proportion of Medicare FFS women beneficiaries with incident
BC persistent with mammography screening in WV and compare it with national estimates from
the SEER-Medicare data
Objective 2: To determine the stage at BC diagnosis among women Medicare FFS beneficiaries
in WV by mammography screening persistence and compare it with the national estimates from
the SEER-Medicare data
Objective 3: To determine the association between persistence with mammography screening
and stage at BC diagnosis among women Medicare FFS beneficiaries in WV,after controlling for
predisposing factors (age), enabling factors (median household income, education level), need
factors (co-occurring chronic conditions), healthcare use (number of primary care physicians
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(PCP) visits in five years before BC diagnosis) and external healthcare environmental factors
(location of residence and number of hospitals offering BC screening/mammography services in
the area of residence), and compare it with the national estimates from the SEER-Medicare data
Specific Aim 2: To determine the timeliness of BC care based on published recommendations
among Medicare FFS beneficiaries in WV and compare it with the national estimates from the
SEER-Medicare data
Objective 1: To determine time to diagnosis and treatment among WV women Medicare FFS
beneficiaries and compare them with the national estimates from the SEER-Medicare data
Objective 2: To determine the proportion of WV women Medicare FFS beneficiaries receiving
timely BC care based on published recommendations and compare it with the national estimates
from the SEER-Medicare data
Objective 3: To identify the factors associated with receipt of timely BC care based on published
recommendations among WV women Medicare FFS beneficiaries and compare them with the
national estimates from the SEER-Medicare data
Objective 4: To determine the association between receipt of timely BC care based on published
recommendations and survival among WV women Medicare FFS beneficiaries, and compare it
with the national estimates from SEER-Medicare data
Specific Aim 3: To determine average total healthcare costs and costs by type of specific
services during the initial phase of 12 months following an incident diagnosis of BC among
Medicare FFS beneficiaries in WV and compare it with the national estimates from SEERMedicare data
Objective 1: To determine average total healthcare costs in initial phase among Medicare FFS
beneficiaries in WV, and compare it with the national estimates from the SEER-Medicare data
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Objective 2: To determine average total healthcare costs by types of specific services in the
initial phase among Medicare FFS beneficiaries in WV, and compare them with the national
estimates from the SEER-Medicare data
Objective 3: To determine the predictors of average total healthcare costs in the initial phase
among Medicare FFS beneficiaries in WV and compare them with the estimates from SEERMedicare data
Objective 4: To determine the magnitude of differences in the average total healthcare costs in
the initial phase between Medicare FFS beneficiaries in WV and those from the SEER-Medicare
using decomposition analysis
CONCEPTUAL FRAMEWORK
The Andersen Behavioral Model for Health Services Utilization (Andersen model) was utilized
as the conceptual model in these studies 60,61. This model that has been used for decades in
predicting health services utilization in population-based studies postulates that healthcare
services utilization is the function of the predisposition of individuals to use services, factors
which enable or impede use, the need for care, healthcare use, and external environmental. This
model is one of the most frequently used conceptual frameworks for analyzing individual’s
utilization of health care services (Figure 1.1).
Predisposing factors such as age, race, and enabling factors such as census tract annual
household income and census tract education level were included in the model. Need-related
factors included in the model were comorbidities, mental conditions, stage at diagnosis, grade of
tumor, estrogen-receptor status, and size of tumor. The later four variables were included only in
Aims 2 and 3. Healthcare use consisted of persistence with mammography screening, primary
care physicians visits, type of initial treatment, and inpatient use. The later two variables were
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included only in Aims 2 and 3. External health care environment factors included in the model
were location of residence and number of hospitals offering BC screening and oncology related
services. Using this Andersen Behavioral model of healthcare services utilization provides a
strong theoretical framework to identify the factors which influence stage at BC diagnosis (Aim
1), timeliness of BC care (Aim 2), and total healthcare costs in the initial period of one year (Aim
3).
SIGNIFICANCE
Aim 1 results from this study will help understand the disparities in stage at the time of BC
diagnosis by persistence with mammography screening among Medicare FFS beneficiaries from
rural setting, such as WV, and how this association varies from national estimates. Aim 2 results
will help to identify disparities in the timeliness of BC care and the factors contributing to timely
diagnosis and treatment and how timely care affect survival among elderly Medicare FFS
beneficiaries diagnosed with BC from a rural setting such as WV, and compare them with the
national sample estimates. Aim 3 results will help to understand average total healthcare costs in
the initial phase, and to what extent age, race, location of residence, type of treatment,
comorbidity burden and clinical variables affect these costs in elderly Medicare FFS
beneficiaries in WV diagnosed with BC and variation from the national estimates will also be
obtained. In addition, comparing average total healthcare costs among elderly Medicare
beneficiaries in WV with incident BC to the national sample will help to determine whether or
not these costs were higher in a rural setting such as WV with higher median age and where the
majority of the elderly women are diagnosed at advanced stages of BC. Overall, this project laid
the foundation for larger studies aimed at decreasing BC disparities in a rural and geographically
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challenged state such as WV, through the development of strategies and interventions to foster
early detection and timely treatment of BC among elderly women.
LIMITATIONS
Since the study utilized administrative claims data, the limitations of these studies include
selection bias, misclassification and coding errors. Data on beneficiaries from the Medicare
managed care program, and uninsured population was not be used, thus the study results may be
generalizable only to FFS beneficiaries. Since information on each patient’s socio-economic
status is not available with SEER-Medicare, the county level census tract median household
income and education level were utilized 62. Medicaid claims for dual-eligible Medicare
beneficiaries in the SEER-Medicare data are not available; therefore, we limited our comparisons
of costs to those incurred only by Medicare for beneficiaries diagnosed with cancer in WV and in
SEER-Medicare. Any screening mammograms obtained outside the Medicare program such as
from free mammography screening programs are not captured by Medicare and hence may affect
the precision of the estimates. This may not be a significant limitation as Medicare is the
primary health insurer for the older adult population. Any genetic factors, family history of BC,
and psychosocial factors such as perceived risk and knowledge about mammography screening
and BC, affecting the screening behavior and incidence of BC are not captured by this database
and hence may affect the precision of the estimates. As per the literature, the FFS beneficiaries
tend to be sicker than those in managed care, thus the costs may be skewed for the beneficiaries.
The costs reported do not include out-of-pocket costs, and hence do not represent total cost of
care during initial one year period. Moreover, costs associated with lost productivity and other
non-medical costs which constitutes important economic burden are not captured by Medicare
and hence are not included. As Medicare data on prescription drugs is not available before 2007,
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the costs associated with adjuvant therapies with prescription drugs such as Tamoxifen were not
be captured and hence not included in the studies.
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CHAPTER 2
ASSOCIATION BETWEEN PERSISTENCE WITH MAMMOGRAPHY SCREENING
AND STAGE AT DIAGNOSIS AMONG ELDERLY WOMEN DIAGNOSED WITH
BREAST CANCER
INTRODUCTION
Breast Cancer
Breast cancer (BC) is the most common cancer and the second leading cause of cancer
death in women in the United States (US). For year 2014, about 232,670 new cases of invasive
BC, and about 62,570 new cases of carcinoma in situ (CIS) will be diagnosed, and 40,000
women will die from BC in the US 1.
BC incidence and mortality rates vary significantly by age. Based on Surveillance,
Epidemiology and End Results (SEER) statistics for 2005-2009, the median age at diagnosis and
mortality due to BC was 61 and 68 years, respectively 2. Also 41% of the new cases of BC were
diagnosed, and 57.4% of the BC deaths occurred in women age 65 and above 2. More than half
of incident BC diagnoses occur in women age 65 and above 3. The overall incidence of BC for
2005-2009 was 82.97 per 100,000 in women age below 65 years and was 421.30 per 100,000 in
women age 65 and above. The overall mortality from BC for 2005-2009 was 11.15 per 100,000
in women below 65 years of age and was 98.64 per 100,000 in women age 65 and above 2.
Moreover, elderly women age 65 and above have a greater burden of BC as tumor in these
women may be found at more advanced stages and with larger sizes thereby leading to poorer
survival 4.
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Mammography Screening
Mammography screening is considered the ‘gold standard’ for women at an average risk
to detect BC at an early stage, when the treatment is less aggressive and most effective 5,6.
Mammography screening has demonstrated a reduction in BC-related mortality by 20-35% in
average-risk women age 40-69 years of age 6-10. Also, women diagnosed with BC who have had
a mammography screening within the previous two years are significantly less likely to have
late-stage disease 11. However, in 2010 only 64% of women age 65 and above have had
mammography screening within the past two years as compared to 73% among women age 5064 years 12 even though annual screening mammograms are covered by both Medicare and
Medicaid. This lower percentage may be partly due to the uncertainty regarding the frequency
and upper age limit to avail mammography screening as reflected in the BC screening guidelines.
The US Preventive Service Task Force recommends biennial mammography screening for
women in age group 69 to 74 years, but reported insufficient evidence for mammography
screening for women age above 74 years 13. In contrast, the American Cancer Society
recommends annual mammography screening with no set upper age limit for women till her life
expectancy is at least five years 14. In absence of no direct evidence of beneficial effects of
mammography screening and with suggested potential and immediate harms of mammography
screening in elderly women age 75 and older, this group encounters contrasting
recommendations and guidelines for mammography screening which may affect their screening
behavior thereby leading to poorer breast cancer outcomes.
Breast Cancer and Mammography Screening in West Virginia
West Virginia (WV), the only state that lies completely in Appalachia is a largely rural
and medically underserved region in the US characterized by high poverty rates, low levels of
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education, aging population, high rates of chronic diseases, and poor health behaviors 15-18. WV
is reported to have higher rates of advanced and unstaged BC 19-23, which has been attributed to
lower mammography screening rates in women in WV 20,21,24,25. Additionally, WV was ranked
sixth nationally in BC deaths in 2008 26,27.
In WV women age 65 years and above, BC accounted for 12% of all the incident cancer
cases 25 and 5.3% of all cancer deaths 28. For 2009 among women age 65 and older, WV had
lower incidence of BC (372.8 per 100,000 vs. 411.7 per 100,000 nationally) but higher mortality
(110.4 per 100,000 vs. 98.6 per 100,000 nationally) 29,30 as compared to the national estimates.
The authors of various studies have argued that low mammography screening rates in WV
women may be one of the significant factors responsible for this disparity 21,25,31.
Persistence with Mammography Screening and Stage at Breast Cancer Diagnosis
Although mammography screening has been reported to reduce BC mortality by 20-35%
in women age 40-69 years 6-10, it is not yet clear whether or not mammography screening is
beneficial in older women. This is because very few screening trials evaluating the benefits of
mammography screening in women have included women aged 70 and above 32. Elderly women
age 65 and above have a greater burden of BC since it is found at more advanced stages and with
larger tumor sizes thereby leading to poorer survival 4. Also, though these women are more
vulnerable to BC, they are less likely to utilize mammography screening 33,34. In 2010, 64% of
women age 65 and above have had mammography screening within the previous 2 years as
compared to 73% among women age 50-64 years 12. Without clear scientific evidence of
benefits of mammography screening in older women, physicians are left with the decision
whether or not to recommend mammography screening to these elderly women. Physicians have
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several mammography screening guidelines from which to choose for this expanding aging
population, when most of the current US-based guidelines have no upper age limit set up.
Even though reducing BC-related mortality is the ultimate goal of mammography
screening, intermediate measures such as stage at diagnosis are useful to evaluate the utility of
screening 35,36. In elderly women age 65 and above, various studies have demonstrated the
benefits of mammography screening utilization on an important predictor of survival, stage at
BC diagnosis. Two studies which used Surveillance Epidemiology and End Results (SEER)Medicare database reported that mammography use decreased with advancing age at diagnosis,
and older women who undergo regular mammography were diagnosed with an earlier stage of
disease 37,38. However, these studies utilized the mammography screening data from only two
years before BC diagnosis, which may have failed to capture the effect of persistence with
mammography screening on the stage at BC diagnosis. Also, a study by McCarthy et al. utilized
SEER data from only three registries which may limit the generalizability of the study findings
37

. A study which utilized 5-years mammography utilization data from all the SEER registries

reported that regular mammography screening was associated with earlier stage at BC diagnosis,
though it focused only on women age 80 and above 39. A systematic review of routine
mammography screening demonstrated that regular mammography screening was associated
with earlier-stage disease and lower BC mortality, but it focused only on women over 74 years of
age 40.
Thus, most of the studies evaluating the association between mammography screening
utilization and stage at BC diagnosis have been conducted using data from either a few SEERMedicare registries, or data for limited time period of two years before BC diagnosis, or among
women age 80 and above. Moreover, the major limitation with all these previous studies is that
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the authors did not use any model or technique to distinguish screening from diagnostic
mammograms which is one of the key concerns with Medicare or any administrative claims data.
A study by Freeman et al. 41 reported that challenges persist in distinguishing screening
mammograms from the diagnostic ones with the Medicare claims data as many screening
procedures may be billed as diagnostic procedures as the later are reimbursed at higher level.
The authors of a recently published study have developed and suggested a 3-step algorithm with
higher sensitivity (99.7%) and higher positive predictive value (97.4%) to distinguish between
screening and diagnostic mammograms using Medicare data linked to a cancer registry 42. In the
absence of strong evidence supporting beneficial effects of mammography screening and hence
no current guidelines supporting mammography screening in older women and in absence of
proper studies focusing on this crucial issue, overall there is a vital need to determine the
association between mammography screening and stage at BC diagnosis among elderly women
age 65 and above, that clearly distinguishes between screening and diagnostic mammograms,
from a large number of SEER-Medicare registries, with a longer follow-up time period of at least
five years before BC diagnosis to capture persistence to mammography screening.
In addition, SEER-Medicare data represents only 17 cancer registries and states/regions
and reflects a population more likely to be residing in urban setting 43. Very limited information
is available about the use of mammography screening and stage at BC diagnosis among elderly
Medicare beneficiaries diagnosed with BC from rural settings and from non-SEER Medicare
states. In contrast to population characteristics prevalent in SEER-Medicare areas, a large
majority of the population in WV is white and a significant proportion resides in rural areas. For
2009, WV had a lower incidence of BC among women age 65 and older (372.8 per 100,000 vs.
410.6 per 100,000) but higher mortality (110.4 per 100,000 vs. 98.6 per 100,000) 29,30 as
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compared to the national estimates. The proportion of WV women who have had a mammogram
in the past two years increased with increase in age until 64 years, but the trend reversed for
those who were age 65 and above 24. Moreover, the overall mammography screening rates in
WV women was also lower than the national estimates 24. Due to higher BC mortality in women
age 65 years and above in WV as compared to national estimates, there is a need to determine
the association between persistence with mammography screening and stage at BC diagnosis in
elderly WV women and compare this with the national estimates.
Hence, the purpose of the study is to determine the persistence with mammography
screening in WV Medicare fee-for-service (FFS) women beneficiaries diagnosed with first
incident BC and compare it with national estimates using SEER-Medicare data and to determine
the association between persistence with mammography screening and stage at BC diagnosis in
these WV women and compare it with the national estimates, after controlling for predisposing
factors (age), enabling factors (median household income, education level), need factors (cooccurring chronic conditions), healthcare use (number of primary care physicians (PCP) visits in
five years before BC diagnosis) and external healthcare environmental factors (location of
residence and number of hospitals offering BC screening/mammography services in the area of
residence).
METHODS
Data Source
West Virginia Cancer Registry-Medicare-Area Resource File linked dataset
Established by the West Virginia Department of Health and Human Resources in 1993,
the West Virginia Cancer Registry (WVCR) is a state-level cancer registry which provides
information on cancer incidence and mortality in West Virginia (WV) 44. The registry collects
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and provides data on the primary site of cancer, tumor grade, date and stage of diagnosis, date
and cause of mortality, and demographics such as age, gender, race, and also zip code
information (for location of residence). The de-identified linked WVCR-Medicare dataset was
established at West Virginia University (WVU) in full compliance with the WVU Institutional
Review Board and HIPPA requirements 45. The WVCR file served as the case source file, and
individuals who were aged ≥ 65 years and diagnosed with cancer between the January 1, 2002
and December 31, 2007 were extracted from this file. The Social security numbers (SSN) for
these individuals was then provided to the CMS by the WVCR, using which the CMS identified
the corresponding Health Insurance Claim (HIC) number. To extract information on the
individuals as Medicare beneficiaries, a “crosswalk” file is created using the HIC which allows
for linkage across the WVCR and the Medicare. Individuals with a missing SSN were excluded
from the linkage. The Area Resource File (ARF) was linked to the WVCR-Medicare dataset
using the state and county FIPS codes for each beneficiary to extract the county level
information on the availability of healthcare facilities, healthcare providers, and socioeconomic
characteristics of the region’s population.
SEER-Medicare-Area Resource File linked dataset
The SEER-Medicare linked dataset provides population-based information on cancerrelated epidemiologic and health services research. The SEER-Medicare program collects
information on newly diagnosed cases of cancer from 17 population-based tumor registries
which in turn collect information from several sources including hospitals, outpatient clinics,
laboratories, private practitioners, laboratories, hospices, autopsy reports and death certificates.
The SEER-Medicare data represents approximately 26% of the US population. The SEER part
of the SEER-Medicare data is in the form of a tailored file known as the Patient Entitlement and
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Diagnosis Summary File (PEDSF). PEDSF contains one record per person for individuals in the
SEER database who have been matched with Medicare enrollment records. These files provide
diagnostic information for up to 10 diagnosed cancer cases (including date of cancer diagnosis,
cancer sub-site, cancer stage at diagnosis, tumor size, histology, grade), and information on the
first course of cancer related treatment (surgery and radiation provided in the first 4 months after
diagnosis) for each individual. The PEDSF additionally includes information on the median
household income and education level for each individual based on their census tract and zip
code data.
The Medicare files that are a part of the SEER-Medicare linked dataset provide
information about any health care utilized by individuals age 65 and above who are enrolled in
and are covered under the Medicare program. These files have claims from the inpatient,
outpatient, physician, home health, and hospice care utilized by individuals enrolled in the
program. The linkage of the SEER data with the Medicare data, and formation of the SEER case
number involves matching individuals across the two files using an algorithm based on a match
of SSN, name, sex, and date of birth. The linkage process is described elsewhere 43. The Area
Resource File (ARF) was linked to the SEER-Medicare dataset using the state and county
Federal Information Processing Standards (FIPS) code for each beneficiary to extract the county
level information on the availability of healthcare facilities and healthcare providers.
Study Design
This study utilized a retrospective observational cohort design to assess the association
between persistence with mammography screening and stage at diagnosis among Medicare FFS
beneficiaries diagnosed with BC.
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Study Cohorts
The two study cohorts consisted of all women from WVCR-Medicare-ARF linked
dataset and SEER-Medicare-ARF linked dataset, age 70 and above at the first primary diagnosis
of incident BC between January 1, 2007 and December 31, 2007. Since mammography
screening persistence during the period of five years before BC diagnosis was to be determined,
women age 70 and above who were continuously enrolled in Medicare parts A and B for at least
60 months before BC diagnosis and till the month of BC diagnosis, and who were not enrolled in
health maintenance organizations (HMOs) at any time during the study period were included in
the study. Women with a previous cancer diagnosis, unknown or missing BC stage information,
and who were diagnosed via death certificate or autopsy were excluded from the study. BC
diagnosis codes were based on the primary site and International Classification of Diseases, 9th
edition Clinical Modification (ICD-9-CM) codes 174.xx, 233.0x, 238.3x, and 239.3x.
According to the WVCR-Medicare-ARF linked dataset, 661 women were diagnosed with
BC from January 1, 2007 to December 31, 2007. The following women were excluded from the
final study population: 168 women who were younger than 70 years at diagnosis, 99 women with
any previous cancer diagnosis, 7 women who were diagnosed with BC during death or autopsy,
56 women for whom BC stage information was unknown or missing, 32 women who were not
continuously enrolled in Medicare parts A and B for 5 years before diagnosis, and 72 women
who were members of HMO any time during the study follow-up period. From the remaining
227 women, only 6 women (2.6%) belonged to ‘other’ race which resulted in very small cell-size
for stage at diagnosis categories, and hence were removed from the analyses. Hence, the cohort
of 221 WV women was included in the final analyses.
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According to the SEER-Medicare-ARF linked dataset, 27,781 women were diagnosed
with BC from January 1, 2007 and December 31, 2007. The following women were excluded
from the final study population: 14,175 women who were younger than 70 years at diagnosis,
721 women with any previous cancer diagnosis, 171 women who were diagnosed with BC
during death or autopsy, 383 women for whom BC stage information was unknown or missing,
770 women who were not continuously enrolled in Medicare parts A and B for 5 years before
diagnosis, and 3,616 women who were members of HMO any time during the study follow-up
period. The remaining 7,945 SEER-Medicare women were eligible to be included in all further
analyses to derive national estimates.
Measures
Dependent Variable: Stage at diagnosis: BC stage at diagnosis was determined according to the
SEER summary staging system which is a combination of the most accurate clinical and
pathological documentation of the extent of disease 46 and which uses all the data in the medical
record. The variable was categorized as an ‘early stage’ consisting of carcinoma insitu and
localized cancers, and the ‘late stage’ consisting of regional and distant cancers as defined in a
previous study 47.
Key Independent Variable: Persistence with mammography screening: There is ambiguity
regarding the ability of Medicare claims data to distinguish screening from diagnostic
mammograms. Appropriately distinguishing screening mammograms from diagnostic
mammograms is very crucial when assessing screening utilization using claims-based database
48

. No clear distinction between screening and diagnostic mammograms may affect

measurement of the effect of mammography screening on BC-related outcomes using Medicare
claims. A recently published 3-step algorithm with high sensitivity (99.7%) and high positive
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predictive value (97.4%) of a screening designation was utilized to classify screening
mammograms from diagnostic mammograms 42.
After capturing the claims for all the mammograms, this 3-step algorithm was applied 42.
It had the following sequential steps:
Step 1: To identify if women had a mammogram in the previous 9 months (<= 270 days): If a
woman had a mammogram within 9 months then those mammograms were removed. If a
woman did not a mammogram within 9 months then those mammograms led to step 2.
Step 2: To identify if the Healthcare Common Procedure Coding System (HCPCS) code for a
mammogram was for ‘screening’ or ‘diagnostic’ purpose: If the HCPCS code for a mammogram
was for ‘screening’ purpose then those mammograms were considered to be screening
mammograms and were utilized to determine persistence with mammography screening. If the
HCPCS code for a mammogram was for ‘diagnostic’ purpose then those mammograms led to
step 3.
Step 3: If identify if a woman had any BC-related symptom 349 days prior to ‘diagnostic’
mammogram: If a woman had a BC-related symptom within 349 days prior to diagnostic
mammogram then those mammograms were removed. While, if a women had a BC-related
symptom beyond 349 days prior to diagnostic mammogram were utilized to determine
persistence with mammography screening.
All the mammograms which had HCPCS codes for ‘screening’ in step 2 and those for which
prior BC-related symptom was beyond 349 days in step 3 were considered to be actual screening
mammograms and were utilized to determine persistence with mammography screening for each
woman in the study cohorts. Using this algorithm improved the precision of estimates for this
study.
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The key independent variable for this study was persistence with mammography
screening defined in the literature as having had at least three consecutive mammograms as per
the screening guidelines 49. Based on the number of screening mammograms a woman had
during the five years period before BC diagnosis, women were categorized as Non-persistent
users (with 0-2 screening mammograms), and Persistent users (with three or more screening
mammograms). As per the recently published study, older women above 65 years of age have
similar risk of advanced stage of BC with biennial screening mammography as compared to
annual screening mammography 50. Hence, persistent users represented a population who have
had annual to biennial screening mammography before BC diagnosis.
Other Independent Variables: To identify the factors that contributed to an early stage at BC
diagnosis associated with persistence with mammography screening, the Andersen behavioral
healthcare services utilization model was used 51,52. Based on this model, the independent
variables were grouped into predisposing factors, enabling factors, need-related factors, factors
associated with healthcare use, and external healthcare environmental factors (Figure 2.1).
Predisposing factors consisted of age at BC diagnosis (70-74, 75-79, 80 and older), race
(white, other), while enabling factors included census tract median household income of their zip
code of residence (=<$35,000; >$35,000), and census tract percentage of people age >= 25 years
with at least 4 years of college education (<15%, >=15%). As individual level information on
household income and education level were not available with both SEER-Medicare and WVCancer Registry, census tract information for these two variables were utilized in this study.
Need-related factor comprised of co-occurring chronic conditions during the twelve months
before BC diagnosis which were identified from the Medicare files using the ICD-9 diagnosis
codes. Comorbidity scores were calculated using Charlson comorbidity index with macros
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provided by the National Cancer Institute 53-55 and were categorized as 0 (no comorbidity), 1, and
2+. Healthcare use factors comprised of number of primary care physicians (PCP) visits in the
five years before BC diagnosis. Similar to previous research, PCP visits were derived from
National Claims History (NCH) files using the Medicare provider specialty field found in NCH
claims and the PCP included those in general practice (01), family practice (08), internal
medicine (11), geriatric medicine (38), and multi-specialty group practice (70) 56. The PCP visits
were categorized into two groups (high, low) based on the median value. External healthcare
environmental factors included location of residence based on US Department of Agriculture
rural-urban continuum codes (metro, urban, rural) and the number of hospitals with BC
screening/mammography services in the area of residence for each woman derived from ARF
file.
Statistical Analyses
Chi-square statistics for categorical variables and t-test test for continuous variables were
used to determine significant differences in persistence to mammography screening categories
across all the independent variables, for both the study cohorts. The percentage of women with
each stage of disease according to persistence with mammography screening was also calculated
for both the study cohorts. For each cohort, logistic regression was performed to determine the
association between screening mammography persistence and an early stage of disease, after
controlling for predisposing, enabling, need, healthcare use and external healthcare
environmental factors. In both the regressions, “late stage” was used as the reference group for
the dependent variable. As the sample size for the WV-Medicare cohort was very small as
compared to the SEER-Medicare cohort and consisted of only white women, 10% of nonHispanic white women from each SEER-Medicare registry were randomly selected to make the
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national cohort comparable to WV cohort. This randomly selected sample had similar
distribution of characteristics as the entire SEER-Medicare non-Hispanic white population (data
not shown). Hence, 708 women comprised of the SEER-Medicare cohort who were included for
further analyses to determine the relationship between type of cohort (WV-Medicare and SEERMedicare) and an early stage of disease, after controlling for all the independent variables.
Logistic regression was performed using “late stage” as the reference group for the dependent
variable. The fit of the regression models were tested by Pearson chi-square and likelihood ratio
chi-square (deviance statistics) and Hosmer-Lemeshow goodness-of-fit statistic 57. From the
logistic regressions, the parameter estimates were transformed to odds ratios and their
corresponding 95% confidence intervals were examined and the findings that were significant
with p-values less than 0.05 levels are discussed. All analyses were conducted within statistical
analysis systems software SAS 9.3 (SAS® version 9.3, SAS Institute Inc., Cary, NC, USA).
RESULTS
Description of the Study Cohorts by Persistence with Mammography Screening
Table 2.1 characterizes WV-Medicare and SEER-Medicare cohorts by persistence with
mammography screening in women age 70 and above, diagnosed with first primary incident BC
in 2007. For the WV-Medicare cohort, younger age at diagnosis was associated with screening
mammography persistence. However for SEER-Medicare cohort, younger age at diagnosis,
being white, higher household income, residence in an area with higher proportion of the
population with higher education, no or one co-occurring condition, and low PCP visits were
associated with screening mammography persistence.
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Stage at Breast Cancer Diagnosis by Persistence with Mammography Screening
Approximately, 51% of women in WV-Medicare cohort were persistent with
mammography screening (Figure 2.2) as compared to 45.4% in the SEER-Medicare cohort
(Figure 2.3). Figure 2.4 describes disease stage according to persistence with mammography
screening during five years before diagnosis for WV-Medicare cohort. Among women who
were not persistent with mammography screening, 31% were diagnosed with the late stage
disease. Among women who were persistent with mammography screening, only 12% were
diagnosed with late stage disease. Figure 2.5 describes disease stage by persistence with
mammography screening during five years before diagnosis for the SEER-Medicare cohort.
Among women who were not persistent with mammography screening, 39% were diagnosed
with late stage disease. Among women who were persistent with mammography screening, 17%
were diagnosed with late stage disease. This indicates that the WV-Medicare cohort had a larger
proportion of women diagnosed at an early stage BC if they were persistent with mammography
screening as compared to the SEER-Medicare cohort.
Association between Persistence with Mammography Screening and Stage at Breast
Cancer Diagnosis
Table 2.2 describes the results of separate multivariate logistic regressions for the
probability of an early stage disease for both the study cohorts. For the WV-Medicare cohort,
women who were persistent with mammography screening were four times more likely of being
diagnosed at an early stage BC (Adjusted odds ratio (AOR) = 4.18, 95% confidence interval (CI)
= 1.94-8.98) as compared to those who were not persistent with mammography screening. No
other factors significantly affected the probability of being diagnosed at an early stage in this
sample. For the SEER-Medicare cohort, women who were persistent with mammography
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screening were significantly more likely to be diagnosed at an early stage BC (AOR = 1.44, 95%
CI = 1.31-1.58) as compared to those who were not persistent with screening mammography.
Among enabling factors, higher household income was significantly associated with more
likelihood of women being diagnosed at an early stage disease (AOR = 1.19, 95% CI = 1.041.35) as compared to those with lower household income. Women who had higher PCP visits
during five years before BC diagnosis were significantly more likely to be diagnosed at an early
stage BC (AOR = 1.17, 95% CI= 1.06-1.28) as compared to those who had lower PCP visits.
Description of the Study Cohorts
Table 2.3 characterizes the significant differences in WV-Medicare and SEER-Medicare
cohorts. The two cohorts were significantly different from each other in terms of enabling
factors such as census tract household income and census tract education level, and external
healthcare environmental factors such as location of residence and number of hospitals with BC
screening services in the area of residence. Elderly women in WV diagnosed with BC were
more likely to reside in rural areas, had lower census tract annual household income, had lower
education levels, and had less access to BC screening centers as compared to those from the
SEER-Medicare cohort.
Differences in Stage at Breast Cancer Diagnosis between Study Cohorts in a Multivariate
Framework
Table 2.4 lists the results of the multivariate logistic regression for the probability of an
early stage disease after combining both WV-Medicare and SEER-Medicare cohorts and
controlling for the type of setting (WV-Medicare vs. SEER-Medicare) and other independent
variables. Women in WV-Medicare cohort were more likely to be diagnosed at an early stage
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disease as compared to women in the SEER-Medicare cohort, however the association was not
significant (AOR = 1.57, 95% CI = 0.97-2.55).
DISCUSSION
As per the literature to date, this is the first study which after appropriately identifying
screening mammograms from the Medicare claims using a recently published algorithm,
evaluated the association between persistence with mammography screening and stage at BC
diagnosis in a rural state such as WV and compared it with the national estimates derived from
the SEER-Medicare data. In the absence of data on persistence with mammography screening
from a rural setting and from non-SEER-Medicare states, this study has filled a significant
literature gap by addressing these issues and improving the precision of the estimates by
appropriately identifying screening mammograms from the Medicare claims. The findings of
this study are consistent to the previous studies which reported that regular mammography
screening or having had a mammography screening in one to two years before BC diagnosis was
associated with earlier disease stage 37,39,40,48.
Approximately 51% of elderly WV women diagnosed with BC were persistent with
mammography screening as compared to 45% from those in the SEER-Medicare cohort. Also in
WV-Medicare cohort, approximately 89% of women with BC were diagnosed with an early
disease if they were persistent with mammography screening as compared to 83% from the
SEER-Medicare cohort. Thus, the arguments made by the authors of the previous studies about
lower mammography screening utilization in WV women as one of the contributing factors to
late stage BC diagnosis 20,24,31 are conflicting with the findings of this study . There may be
other factors such as poor health status, family history of BC, BRCA gene mutation, untimely
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and inappropriate care, that may be responsible for higher rates of late stage BC in elderly
women in WV.
Even though WV women were more likely to reside in rural regions, had lower income
and education levels, and had lower access to BC screening centers as compared to women from
the SEER-Medicare regions, the likelihood of being diagnosed with an earlier stage BC was
higher for WV women who were persistent with mammography screening (AOR=4.18) as
compared to women belonging to the SEER-Medicare cohort (AOR=1.44). This indicates that
enabling factors and external healthcare environmental factors had no negative impact on
persistence with mammography screening in WV women diagnosed with BC, and they were
diagnosed at earlier stages when the treatments are usually less aggressive, and survival is
significantly better. Among all the independent variables controlled in the model, only
persistence with mammography screening was significantly associated with an earlier stage of
disease in elderly WV women which indicates that persistence with mammography screening is
extremely beneficial in these women to get diagnosed at an earlier stage of BC. However, for
the SEER-Medicare cohort, along with persistence with mammography screening, enabling
factor such as higher census tract household income and healthcare use in terms of higher PCP
visits significantly increased the likelihood of earlier representation of BC. This indicates that
women who have higher PCP visits are more likely to be consulted for healthy preventive
behaviors such as mammography screening, and are more likely to get screening at regular
intervals thereby being able to get diagnosed at an earlier stage of BC.
When controlled for the type of setting (WV-Medicare vs SEER-Medicare) along with
persistence with mammography screening and other independent variables, WV-Medicare cohort
was more likely to be diagnosed at an earlier stage BC as compared to the SEER-Medicare
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sample, but the association was not significant. This indicates that elderly women in WV are
equally likely to be diagnosed at an early stage BC as women in the SEER-Medicare sample.
A major strength of this study is it helps in understanding the benefits of persistence with
mammography screening for elderly women age 70 and above in a rural setting such as WV and
how it differs from the national estimates obtained from the SEER-Medicare regions. Utilization
of the recently published algorithm with very high sensitivity (99.7%) and high predictive value
(97.4%) to identify the screening mammograms from the Medicare claims files 42 may have
improved the precision of the estimates and hence must also be considered a major strength of
the study. Though it is very crucial in appropriately distinguishing screening from diagnostic
mammograms when evaluating screening utilization from claims-based data 48, difficulty in this
distinction has been reported as a major limitation by several previous studies which have
evaluated the association between utilization of mammography screening and stage at BC
diagnosis 37,39,40,48.
There are several limitations worth noting when interpreting the results of this study.
Some of the study women may have been recipients of free screening mammograms which will
not be captured in the Medicare data and hence may underestimate persistence with
mammography screening. However, this may not be considered a major limitation as Medicare
is the primary health insurer for all of the older adult population. Since the study utilized cancer
registries-Medicare linked databases, certain patient characteristics such as annual household
income, education level, access to total of BC screening centers at patient level are not available
and hence census tract information for these variables has been utilized 58. The findings of the
study are generalizable only to elderly women age 70 and above, and to other rural areas having
same characteristics as that of WV.
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CONCLUSION
The findings of the study indicate that persistence with mammography screening is
significantly associated with earlier stage at BC diagnosis in elderly women in WV, and the
likelihood of earlier representation of disease was similar in WV as compared to the national
cohort derived from the SEER-Medicare registries.
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Figure 2.1: The Andersen Behavioral Model for Health Care Utilization (For Aim 1)
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Table 2.1
Description of the Study Cohorts by Persistence with Mammography Screening
2007
Variables
WV-Medicare (N=221)
SEER-Medicare (N=7,945)
NonNonPersistent
%
Persistent
%
Sig Persistent
%
Persistent
%
108
113
4341
3604
(48.9%)
(51.1%)
(54.6%)
(45.4%)
Stage at BC Diagnosis
***
Early
75
69.4
100
88.5
2653
61.1
3000
83.2
Late
33
30.6
13
11.5
1688
38.9
604
16.8
Age at Diagnosis
*
70-74
34
31.5
38
33.6
1183
27.3
1325
36.8
75-79
23
21.3
38
33.6
1141
26.3
1094
30.4
80,+
51
47.2
37
32.7
2017
46.5
1185
32.9
Race/Ethnicity
White
NA
NA
NA
NA
3753
86.5
3242
90.0
Other
NA
NA
NA
NA
588
13.5
362
10.0
Location of Residence
Metro
65
60.2
55
48.7
3609
83.1
3018
83.7
Urban
23
21.3
40
35.4
633
14.6
530
14.7
Rural
20
18.5
18
15.9
99
2.3
56
1.6
Census Tract Household Income
LE $35,000
95
88.0
102
90.3
1200
27.6
783
21.7
GT $35,000
13
12.0
11
9.7
3141
72.4
2821
78.3
Census Tract Education
LT 15% pop. with
CE
44
40.7
57
50.4
1462
33.7
943
26.2
GE 15% pop.
with CE
64
59.3
56
49.6
2879
66.3
2661
73.8
Comorbidity
0
45
41.7
60
53.1
2143
49.4
1959
54.4
1
33
30.6
30
26.5
1235
28.4
1048
29.1
2,+
30
27.8
23
20.4
963
22.2
597
16.6
PCP visits
High
54
50.0
55
48.7
2275
52.4
1650
45.8
Low
54
50.0
58
51.3
2066
47.6
1954
54.2
Total BC Screening Centers
Mean
1.5
1.6
7.0
6.6

Sig

***

***

***

***

***

***

***

Note: Based on 221 elderly WV-Medicare women and 7,945 elderly SEER-Medicare women, age 70 and above diagnosed with
primary incident breast cancer in 2007. WV, West Virginia; SEER, Surveillance, Epidemiology, and End Results; PCP, Primary
Care Physicians, BC, Breast Cancer; pop., population; LE, Less than or equal to; GT, Greater than; LT, Less than; GE, Greater
than or equal to; CE, College education; Sig, Significance; NA, Not Applicable. For WV-Medicare cohort, χ2 test for
race/ethnicity variable was not performed due to 0 sample size in one of the persistent groups. Asterisks represent statistically
significant group differences based on χ2 tests and t-tests separately for two study cohorts: ***P<0.001; **001<=P<.01;
*.01<=P<.05.
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Table 2.2
Association between Persistence with Mammography Screening and Stage at Breast Cancer Diagnosis,
Separately for WV-Medicare and SEER-Medicare
Adjusted Odds Ratios and 95% Confidence Intervals from Logistic Regressions
2007
Variables
WV-Medicare (N=221)
SEER-Medicare (N=7,945)
AOR
95% CI
Sig
AOR
95% CI
Sig
Persistence with Mammography Screening
Persistent
4.18 [1.94,8.98]
1.44
[1.31,1.58]
***
***
Non-Persistent
1
1
Age at Diagnosis
70-74
1
1
75-79
0.75 [0.31,1.79]
1.04
[0.92,1.16]
80,+
1.72 [0.73,4.07]
1.11
[1.00,1.23]
Race/Ethnicity
White
NA
NA
1.1
[0.95,1.26]
Other
NA
NA
1
Location of Residence
Metro
1
1
Urban
1.13 [0.44,2.87]
1.07
[0.93,1.23]
Rural
1.00 [0.31,3.15]
1
[0.72,1.39]
Census Tract Household Income
LE $35,000
1
1
GT $35,000
0.77 [0.21,2.85]
1.19
[1.04,1.35]
**
Census Tract Education
LT 15% pop. with
CE
1
1
GE 15% pop. with
CE
2.3 [0.90,5.86]
1.1
[0.98,1.24]
Comorbidity
0
1
1
1
0.72 [0.31,1.65]
0.97
[0.87,1.08]
2,+
0.89 [0.36,2.24]
1.04
[0.92,1.18]
PCP visits
High
1.24 [0.60,2.56]
1.17
[1.06,1.28]
**
Low
1
1
0.85 [0.52,1.38]
1.00
[1.00,1.01]
Total BC Screening Centers
Note: Based on 221 elderly WV-Medicare women and 7,945 elderly SEER-Medicare women, age 70 and
above diagnosed with primary incident breast cancer in 2007. WV, West Virginia; SEER, Surveillance,
Epidemiology, and End Results; PCP, Primary Care Physicians, BC, Breast Cancer; CE, College Education;
pop., population; LE, Less than or equal to; GT, Greater than; LT, Less than; GE, Greater than or equal to;
AOR, Adjusted odds ratio; CI, Confidence Interval; Sig, Significance; NA, Not Applicable. The regressions
also include intercept terms and parameter estimates for other variable controlled are not presented. "Late
Stage at Breast Cancer Diagnosis" is the reference group for the dependent variable for both the study
cohorts. For WV-Medicare cohort, logistic regression did not include race/ethnicity as one of the controlled
variables due to 0 sample size in one of the persistent groups. Asterisks represent statistically significant
group differences compared with the reference group: ***P<0.001; **001<=P<.01; *.01<=P<.05.
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Table 2.3
Description of WV-Medicare and SEER-Medicare (randomly selected non-Hispanic white SEERMedicare) cohorts
2007
WV-Medicare
SEER-Medicare
Variables
(N=221)
(N=708)
N
%
N
%
Sig
Stage at BC Diagnosis
Early
175
79.2
514
72.6
Late
46
20.8
194
27.4
Persistence with Mammography Screening
Persistent
113
51.1
339
47.9
Non-Persistent
108
48.9
369
52.1
Age at Diagnosis
70-74
72
32.6
242
34.2
75-79
61
27.6
179
25.3
80,+
88
39.8
287
40.5
Location of Residence
***
Metro
120
54.3
580
81.9
Urban
63
28.5
120
16.9
Rural
38
17.2
8
1.1
Census Tract Household Income
***
LE $35,000
197
89.1
147
20.8
GT $35,000
24
10.9
561
79.2
Census Tract Education
***
LT 15% pop. with CE
101
45.7
192
27.1
GE 15% pop. with CE
120
54.3
516
72.9
Comorbidity
0
105
47.5
374
52.8
1
63
28.5
193
27.3
2,+
53
24.0
141
19.9
PCP visits
High
112
50.7
325
45.9
Low
109
49.3
383
54.1
Total BC Screening Centers
Mean
1.5
6.5
***
Note: Based on 221 elderly WV-Medicare women and randomly selected non-Hispanic white 708
elderly SEER-Medicare women, age 70 and above diagnosed with primary incident breast cancer in
2007. WV, West Virginia; SEER, Surveillance, Epidemiology, and End Results; PCP, Primary Care
Physicians, BC, Breast Cancer; pop., population; CE, College Education; LE, Less than or equal to; GT,
Greater than; LT, Less than; GE, Greater than or equal to; Sig, Significance. Asterisks represent
statistically significant group differences based on χ2 tests and t-tests: ***P<0.001; **001<=P<.01;
*.01<=P<.05.
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Table 2.4
Differences in Stage at Breast Cancer Diagnosis between Study Cohorts
In a Multivariate Framework
Adjusted Odds Ratio and 95% Confidence Intervals from Logistic Regression
2007
Variables
Early Stage at Diagnosis
AOR

95% CI

Sig

Type of Setting
WV-Medicare
SEER-Medicare
Persistence with Mammography Screening
Persistent
Non-Persistent
Age at Diagnosis
70-74
75-79
80,+

1.57
1

[0.97,2.55]

2.87
1

[2.08,3.97]

***

1
0.63
0.94

[0.42,0.93]
[0.65,1.36]

*

1
0.99
1.12

[0.65,1.50]
[0.51,2.47]

1
1.05

[0.66,1.67]

1
1.60

[1.07,2.40]

1
0.82
1.06

[0.57,1.18]
[0.70,1.61]

Location of Residence
Metro
Urban
Rural
Census Tract Household Income
LE $35,000
GT $35,000
Census Tract Education
LT 15% pop. with CE
GE 15% pop. with CE
Comorbidity
0
1
2,+
PCP visits
High
Low
Total BC Screening Centers

1.24
1
1.00

*

[0.89,1.71]
[0.98,1.02]

Note: Based on 221 elderly WV women and 708 randomly selected non-Hispanic elderly women from
SEER-Medicare, age 70 and above diagnosed with primary incident breast cancer in 2007. WV, West
Virginia; SEER, Surveillance, Epidemiology, and End Results; PCP, Primary Care Physicians, BC,
Breast Cancer; CE, College Education; pop., population; LE, Less than or equal to; GT, Greater than;
LT, Less than; GE, Greater than or equal to; AOR, Adjusted odds ratio; CI, Confidence Interval; Sig,
Significance. The regressions also include intercept terms and parameter estimates for other variable
controlled are not presented. "Late Stage at Breast Cancer Diagnosis" is the reference group for the
dependent variable. Asterisks represent statistically significant group differences compared with the
reference group: ***P<0.001; **001<=P<.01 ; *.01<=P<.05.
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CHAPTER 3
TIMELY DIAGNOSIS AND TREATMENT OF BREAST CANCER IN ELDERLY
WOMEN
INTRODUCTION
Breast Cancer
Breast cancer (BC) is the most common occurring cancer in women and is the second
leading cause of cancer death in women in the United States (US). As per the Surveillance,
Epidemiology and End Results (SEER) statistics for 2005-2009, the overall incidence of BC was
82.97 per 100,000 women in those below 65 years of age and was 421.30 per 100,000 women in
those age 65 and above 1 and the overall mortality from BC was 11.15 per 100,000 women in
those below 65 years of age and was 98.64 per 100,000 women in those age 65 and above 1.
Moreover, older women age 65 and above have a greater burden of BC as cancer in these women
may be found at more advanced stages and with larger tumor sizes thereby leading to poorer
survival 2. However, BC has 5-years survival of 88.5% in elderly women age 65 and above
which is only a little lower as compared to 89.7% for women below 65 years of age 3.
Timely Diagnosis and Treatment of Breast Cancer in Elderly Women
BC is a major and complex health issue among women and the second cause of cancerrelated deaths among women in the US, as such, measuring quality of care delivered to BC
patients is challenging. Timeliness of care, i.e., rapid diagnosis after noticing abnormality in the
breast and rapid initiation of treatment after diagnosis, is one of the key components of highquality cancer treatment. Determining timeliness of care provided to BC patients is extremely
important as both patients and referring care providers expect rapid access to care for breast
problems 4,5. Also, emotional distress may occur during the wait time for the patient’s diagnostic
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evaluation and subsequent treatment 6-8. Most research in this area has demonstrated a possible
relationship between delay and survival because of a complex interaction of clinical and sociocultural factors 9.
To our knowledge, despite the widely accepted benefit of timely care in BC patients, USbased agencies such as the National Initiative for Cancer Care Quality, National Comprehensive
Cancer Network Quality, American Society of Clinical Oncology, National Quality Forum are
yet to define guidelines for an appropriate time frame from presentation of abnormality to
confirmed diagnosis and from diagnosis to the initiation of the treatment 10. As per a quality
review of the timeliness of BC diagnosis and treatment 11, the European Society of Breast Cancer
Specialists (EUSOMA) has published professional opinion-based guidelines on time intervals
between various events from presentation of abnormality to diagnosis of BC 12,13. Moreover, the
National Health Service of United Kingdom has published professional opinion-based guidelines
on appropriate time interval from BC diagnosis to the initiation of the treatment 14. The USbased National Initiative of Cancer Care Quality (NICCQ) has suggested time intervals for few
events which occur between presentation of abnormality to initiation of treatment, however it
does not define the appropriate time from presentation of abnormality to confirmed diagnosis
and from diagnosis to the initiation of the treatment 15.
Despite numerous studies about timeliness of BC care have been conducted in the last
decade in the US 16-24, no consensus exists regarding the time intervals for diagnosis and
treatment delays. Among the studies about delay in diagnosis, only three studies included
women age 65 and above in their analyses 16,19,20. One study did not assess the effect of
important clinical covariates such as tumor size, grade of tumor, ER- and PR-status, socioeconomic variables such as income and education, and access factors, which affect timely
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diagnosis and care 20. While other two studies were conducted in a smaller geographic location
which may affect the generalizability of the findings to other populations 16,19. Among studies
about delay of treatment, only four studies included women age 65 years and above in their
analyses 21-24. One study restricted women till 72 years of age and did not adjust for any clinical
covariates which affect treatment delays 21. Another study was limited to North CarolinaMedicaid population only which may affect the generalizability of the findings to the other
populations 22. Only two studies were conducted using SEER-Medicare dataset of which one
study did not include patients with distant or stage IV disease and did not adjust for clinical
covariates and access factors in the analyses 24, and the other study reported treatment delay in
terms of months (whole numbers), which was not consistent with any of the studies estimating
delay in care 23. Finally, none of the above studies followed the published opinion-based
EUSOMA, National Health Service of United Kingdom or any guidelines to define timeliness of
diagnosis and treatment in women with BC.
As older women age 65 years and above have higher BC incidence and mortality and are
more likely to have advanced stage disease with larger tumors 1,2, it is highly likely that
diagnosis delay and/or treatment delay may negatively affect the prognosis of the disease and
hence the survival. Hence, it is extremely important to determine timeliness of care based on the
published opinion-based guidelines among elderly BC patients in the US.
WV is the only state that lies entirely in Appalachia, a region which is a predominantly
rural and medically underserved in the United States characterized by high poverty rates, low
levels of education, aging population, high rates of chronic disease, and poor health behaviors 2528

. With lower incidence of BC among WV women age 65 and older (372.8 per 100,000 vs.

410.6 per 100,000) but higher mortality (110.4 per 100,000 vs. 98.6 per 100,000) 29,30 as
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compared to the national estimates, and with higher rates of advanced and unstaged BC in these
women 31-35, it is likely that timeliness of care may be one of the significant contributors to these
disparities. Therefore, a study comparing the timeliness of care among elderly BC patients from
WV to the national estimates may help understand these disparities.
Hence, the purpose of the study is to determine timeliness of BC care based on published
recommendations and its effect on survival in elderly women with BC among WV Medicare feefor-service (FFS) women beneficiaries and compare it with the national estimates derived from
SEER-Medicare data, and to determine the factors associated with timeliness of BC care in WV
women and compare it with the national estimates, after controlling for predisposing factors
(age, race), enabling factors (median household income, education level), need-related factors
(stage at diagnosis, grade of tumor, estrogen-receptor (ER) status, co-occurring chronic
conditions), factors associated with healthcare use (number of primary care physicians (PCP)
visits in year prior to BC diagnosis, type of initial cancer-related treatment) and external
healthcare environmental factors (location of residence and number of hospitals offering
oncology services in the area of residence).
METHODS
Data Source
West Virginia Cancer Registry-Medicare-Area Resource File linked dataset
Established in 1993 by the West Virginia Department of Health and Human Resources,
the West Virginia Cancer Registry (WVCR) provides information on cancer incidence and
mortality in the state 36. The registry provides information on clinical characteristics of cancer
such as primary cancer site, tumor grade, date and stage of diagnosis, date and cause of
mortality, and demographic data on age, gender, race, and zip code. In the full compliance with
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the WVU Institutional Review Board and HIPPA requirements, the de-identified linked WVCRMedicare dataset was established at West Virginia University which provided information about
WV individuals who are age ≥ 65 years and diagnosed with cancer between the January 1, 2002
and December 31, 2007 37. The Social security numbers (SSN) for individuals in WVCR were
then provided to the CMS by the WVCR, using which the CMS identified the corresponding
Health Insurance Claim (HIC) number. A “crosswalk” file created using the HIC allowed for
linkage across the WVCR and the Medicare for extracting information on these individuals as
Medicare beneficiaries. Individuals with a missing SSN were excluded from the linkage. To
extract the county level information on the availability of healthcare facilities, and
socioeconomic characteristics of the region’s population, the Area Resource File (ARF) was
linked to the WVCR-Medicare dataset using the state and county FIPS codes for each
beneficiary.
SEER-Medicare-Area Resource File linked dataset
The SEER-Medicare linked dataset provides important data useful for population-level
cancer-related epidemiologic and health outcomes studies. The SEER-Medicare program
collects information on newly diagnosed cases of cancer from 17 population-based tumor
registries which ultimately collect information from hospitals, outpatient clinics, laboratories,
private practitioners, laboratories, hospices, autopsy reports and death certificates and it
represents 26% of the US population. Patient Entitlement and Diagnosis Summary File (PEDSF)
is a customized file which contains one record per person for individuals in the SEER part of the
SEER-Medicare database who have been matched with Medicare enrollment records. PEDSF
provides diagnostic information for up to 10 diagnosed cancer cases (including date of cancer
diagnosis, cancer sub-site, cancer stage at diagnosis), and information on the first course of
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cancer related treatment (surgery and radiation provided in the first 4 months after diagnosis) for
each individual. Additionally it includes information on the median household income and
education level for each individual based on their census tract and zip code data.
The Medicare files of the SEER-Medicare linked dataset provide data about health care
utilization inpatient, outpatient, physician, home health, and hospice care by individuals age 65
and above who are enrolled in the Medicare program. These files have information about dates
of healthcare service and codes for specific diagnosis and procedures using the International
Classification of Disease, Ninth Edition (ICD-9) codes or Common Procedure Terminology
codes. The linkage process of the SEER data with the Medicare data is described elsewhere 38.
The Area Resource File (ARF) was linked to the SEER-Medicare dataset using the state and
county Federal Information Processing Standards (FIPS) code for each beneficiary to extract the
county level information on the availability of healthcare facilities and healthcare providers.
Study Design
This study utilized a retrospective observational cohort design to assess time to diagnosis
and time to treatment and its effect on chances of being alive among Medicare FFS beneficiaries
diagnosed with BC.
Study Cohorts
The two cohorts for this study consisted of women from WVCR-Medicare-ARF linked
dataset and SEER-Medicare-ARF linked dataset, age 66 and older at the first primary
pathologically confirmed diagnosis of incident BC from January 1, 2003 to December 31, 2006.
These women were required to be continuously enrolled in Medicare parts A and B at least 12
months prior to the BC diagnosis to identify comorbidities and timeliness of care from the initial
consultation to BC diagnosis, and till the follow-up period of 12 months after BC diagnosis to
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determine timeliness of care from diagnosis to treatment. Women who died during the study
period and who were enrolled in health maintenance organizations (HMOs) at any time during
the study period were excluded from the study. Also, women with any previous cancer
diagnosis, with unknown or missing stage of BC, and who were diagnosed through death
certificate or autopsy were excluded from the study. To determine the effect of timeliness of
care on the probability of being alive, women diagnosed with first primary pathologically
confirmed incident BC from January 1, 2003 to December 31, 2004 and who followed all the
inclusion and exclusion criteria as described above were identified from both the datasets and
were followed for three years. BC diagnosis codes were based on the primary site and
International Classification of Diseases, 9th edition Clinical Modification (ICD-9-CM) codes
174.xx, 233.0x, 238.3x, and 239.3x.
The WVCR-Medicare-ARF linked dataset identified 2,814 women diagnosed with BC
from January 1, 2003 to December 31, 2006. The following women were excluded from the
final study population: 152 women who were below 66 years at diagnosis, 527 women with any
previous cancer diagnosis, 24 women who were diagnosed with BC during death or autopsy, 246
women with unknown or missing BC stage, 245 women who were not continuously enrolled in
Medicare parts A and B in the 12 months before and 12 months after diagnosis, and 232 women
who were members of a HMO any time during the study period. Thus, a final sample of 1,388
women who had claims for breast biopsy was included in the final analyses.
The SEER-Medicare-ARF linked dataset had 112,719 women diagnosed with BC from
January 1, 2003 to December 31, 2006. The following women were excluded from the final
study population: 45,198 women who were below 66 years at diagnosis, 3,385 women with any
previous cancer diagnosis, 815 women who were diagnosed with BC during death or autopsy,
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1,947 women with unknown or missing BC stage, 5,714 women who were not continuously
enrolled in Medicare parts A and B in 12 months before and 12 months after diagnosis, 14,671
women who were members of a HMO any time during the study period, and 7 women from all
the remaining women who died during the 12 months after BC diagnosis. From the remaining
40,982 women, 4,706 women did not have claims for breast biopsy which were used to ascertain
biopsy-proved diagnosis and hence were removed from the analyses. Thus, a final sample of
36,276 women was included in the final analyses.
Measures
Timely Care Intervals
Based on previous studies 16,17, two intervals were created for both the study cohorts:
timely diagnosis, timely treatment and timely clinical care.
Timely Diagnosis: Timely diagnosis was defined as the period (in days) between the initial
consultation for abnormality and biopsy-proved BC diagnosis as per the published opinion-based
guidelines. Breast biopsies (fine-needle aspiration, core biopsy, incision, or excision) were
identified using Current Procedural Terminology (CPT) and International Classification of
Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) procedure codes. The initial
consultation date for abnormality was defined as the date of a consultation for breast symptoms
or date of diagnostic mammography or diagnostic magnetic resonance imaging (MRI) or
diagnostic ultrasonography. Breast symptoms were identified using International Classification
of Diseases, Ninth Revision, Clinical Modification diagnostic codes 611.7x and 611.9 occurring
within one year before the breast biopsy proved diagnosis date. Diagnostic mammograms were
identified using CPT codes 76090, 76091, 77055, 77056, G0204, G0206. Diagnostic MRI was
identified using CPT codes 76093, 76094, 77058, 77059, C8903-C8908 and diagnostic
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ultrasonography was identified using CPT code 76645. According to the published guidelines of
the EUSOMA on quality assurance in the diagnosis of breast disease 12,13, the number of days
from abnormality in the form of breast symptom or diagnostic procedure to the confirmed BC
diagnosis range from 21 days (3 weeks) to 35 days (5 weeks). This range is calculated based on
the guideline recommended time interval for each event and the typical sequence of events
leading to diagnosis of BC depending on the type of abnormality. Hence, diagnosis delay was
categorized into two groups based on the number of days from initial consultation for
abnormality to biopsy-proved BC diagnosis (timely diagnosis - 35 days or less, and delayed
diagnosis - greater than 35 days).
Timely Treatment: Timely treatment was defined as the period (in days) between biopsy-proven
BC diagnosis and the initiation of treatment as per the published opinion-based guidelines.
Treatment was defined as definitive surgery, neoadjuvant chemotherapy or radiation, whichever
came first. The use of prescription drug was not included in the analysis as data pertaining to
prescription drugs was not available for these study cohorts. According to the only published BC
care guidelines by National Health Service of United Kingdom on timeliness to BC treatment,
the initiation of treatment should occur within less than or equal to 4 weeks (28 days) after BC
diagnosis 14. Based on this guideline, timely treatment was categorized into two groups based on
number of days from biopsy-proved BC diagnosis to initiation of the treatment (timely treatment
- 28 days or less, and delayed treatment - greater than 28 days).
Independent Variables: To identify the factors associated with timely BC care in elderly
Medicare FFS with first primary incident BC, the Andersen behavioral healthcare services
utilization model was utilized 39,40. Based on this model, the independent variables were grouped
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into predisposing factors, enabling factors, need-related factors, healthcare use factors and
external healthcare environmental factors (Figure 3.1).
Predisposing factors included age at diagnosis (66-69, 70-74, 75-79, 80 and older), and
race (white, other), and enabling factors included census tract median household income
(=<$35,000; >$35,000), and census tract percentage of people age >= 25 years with at least 4
years of college education (<15%, >=15%). As individual level information on household
income and education level are not available with both SEER-Medicare and WVCR-Medicare
datasets, census tract information for these two variables was used. Need-related factors
consisted of clinical covariates such as stage at diagnosis (insitu, local, regional, distant), grade
of tumor (well-differentiated, moderately differentiated, poorly differentiated,
undifferentiated/unknown), estrogen-receptor status (positive, negative, borderline/unknown),
tumor size (<1 cm, 1-2 cm, 2-3 cm, >3 cm), and comorbidity scores obtained from co-occurring
chronic conditions during the 12 months prior to BC diagnosis identified from the Medicare files
using the ICD-9-CM diagnosis codes. As stage at BC diagnosis is considered as a predictor or
outcome of delay and as chemotherapy treatment choices are determined by stage, and tumor
size, grade of tumor, estrogen receptor status 41, these variables were included in the analyses.
BC stage at diagnosis was determined according to the SEER Summary staging system that uses
all information available in the medical record. It is a combination of the most precise clinical
and pathological documentation of the extent of disease 42. Comorbidity scores were calculated
using Charlson comorbidity index to account for possible misclassification using codes from
physician claims with macros provided by the National Cancer Institute 43-45. The comorbidity
scores were categorized as 0 (no comorbidity), 1, 2+. The number of primary care physicians
(PCP) visits 12 months prior to BC diagnosis was included as a healthcare use factor in the
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model and its median value was utilized to categorize as low or high. External healthcare
environmental factors included location of residence (metro, non-metro) and ARF-derived
number of hospitals offering oncology-related services and number of hospitals offering BC
screening and mammography services in the area of residence, both categorized as low or high
based on their respective median values.
Statistical Analyses
Descriptive statistics and chi-square statistics were used to describe the characteristics
and the significant differences in characteristics between the two study cohorts. Unadjusted
median time to diagnosis (in days) in women who had any initial consultation and median time
to treatment (in days) in women who had any BC treatment, with their respective 25% and 75%
inter quartile range (IQR) were estimated for both the study cohorts. These time periods (median
days with IQR) were also estimated for all the groups within each independent variable. In
addition, a non-parametric test, Kruskal-Wallis test, was performed to assess statistical
significant differences in time period for diagnosis and treatment within each group. Bar charts
were used to exhibit timely diagnosis and timely treatment based on published opinion-based
recommendations for both the Medicare study cohorts. Separate logistic regression models were
used to characterize timely diagnosis and timely treatment based on published opinion-based
recommendations for both the study populations to identify the predictors of timely care, after
controlling for all the independent variables. Logistic regressions were also conducted on timely
diagnosis and timely treatment to determine significant differences in timely care between WVMedicare and SEER-Medicare cohorts. In all models, “delayed care” for diagnosis and
treatment were used as the reference group for the dependent variables. Another set of logistic
regressions to model the association between timely diagnosis and timely treatment and survival,
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were performed to determine significant differences in survival between WV-Medicare and
SEER-Medicare cohorts. In these regressions, “death” was used as the reference group for the
dependent variable. From all the logistic regressions, the parameter estimates were transformed
to odds ratios, and their corresponding 95% confidence intervals were examined. The findings
that were significant with p-values less than 0.05 levels are discussed. All analyses were
conducted within statistical analysis system software SAS 9.3 (SAS® version 9.3, SAS Institute
Inc., Cary, NC, USA).
RESULTS
Description of the Study Cohorts
Table 3.1 describes the WV-Medicare and SEER-Medicare women age 66 and above,
diagnosed with first primary incident BC in 2003-2006. Twenty-five percent of women in WV
cohort were age 80 and above as compared to 29% in SEER-Medicare. Approximately 98% of
the WV-Medicare women were white as compared to 89% in the SEER-Medicare cohort. A
higher proportion of WV-Medicare cohort had household income below $35,000 (91%), resided
in areas with less than 15% population with some college education (51%), and resided in areas
with lower number of hospitals with oncology services (60%) and BC screening centers (58%).
However, a majority of SEER-Medicare women resided in metro areas (84%), had household
income above $35,000 (75%), resided in areas with greater than 15% of population with some
college education (70%), and resided in areas with lower number of hospitals with oncology
services (56%) and BC screening centers (51%).
Median Days for Diagnosis and Treatment for the Study Cohorts
Table 3.2 describes median time period in days with IQR for diagnosis and treatment in
the WV-Medicare and SEER-Medicare cohorts. The median days from initial consultation for
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abnormality to BC diagnosis was 26 (IQR=12-50 days) for the WV-Medicare cohort as
compared to 20 (IQR=8 to 41 days) for the SEER-Medicare cohort. The overall median days
from BC diagnosis to any BC treatment was 8 (IQR=0-28 days) for the WV-Medicare cohort as
compared to 15 (IQR=0-29 days) for the SEER-Medicare cohort. Among women who had their
first BC treatment as surgery, the median days from BC diagnosis to surgery was 0 (IQR=0-25
days) for the WV-Medicare cohort as compared to 14 (IQR=0-29 days) for the SEER-Medicare
cohort. Women who had their first BC treatment as chemotherapy, the median days from BC
diagnosis to chemotherapy was 20 (IQR=15-29 days) for the WV-Medicare cohort as compared
to 25 (IQR=14-45 days) for the SEER-Medicare cohort. However, women who had their first
BC treatment as radiation therapy, the median days from BC diagnosis to radiation therapy was
27 (IQR=16-48 days) for the WV-Medicare cohort as compared to 28 (IQR=15-49 days) for the
SEER-Medicare cohort.
Median Days for Type of Initial Treatment by Stage at Diagnosis for the Study Cohorts
Table 3.3 describes median time period in days with IQR for type of initial treatment by
stage at BC diagnosis in the WV-Medicare and SEER-Medicare cohorts. The median days from
BC diagnosis to surgery as the first treatment increased with advancing stage of tumor for the
WV-Medicare cohort. It was 0 days for insitu tumor and 10 days for distant tumor. However,
the median days from BC diagnosis to surgery as the first treatment did not vary much by stage
at diagnosis for the SEER-Medicare cohort. It was 11 days for insitu tumor and 14 days for
distant tumor. The median days from BC diagnosis to first treatment with chemotherapy ranged
from 17 (distant tumor) to 178 (insitu tumor) for the WV-Medicare cohort. While the median
days from BC diagnosis to first treatment with chemotherapy were 21 for insitu, 29 for local, 25
for regional and 24 for distant tumors for women in the SEER-Medicare cohort. The median

66

days from BC diagnosis to radiation therapy as the first treatment were 31 for insitu, 27 for local,
17 for regional and 25 for distant tumors for women in the WV-Medicare cohort. However, the
median days from BC diagnosis to radiation therapy as the first treatment were 28 for insitu, 30
for local, 29 for regional and 13 for distant tumors for women in the SEER-Medicare cohort.
Median Days for Diagnosis and Treatment within Independent Variables for the Study
Cohorts
Table 3.4 describes the significant differences in time period in median days with
respective IQR for diagnosis and treatment within each independent variable for both the study
cohorts. For the WV-Medicare cohort, median time period for diagnosis was significantly
different for stage at diagnosis, grade of tumor and tumor size. While for the SEER-Medicare
cohort, median time period for diagnosis was significantly different for all the independent
variables except census tract income and education. For the WV-Medicare cohort, median time
period for treatment was significantly different for age at diagnosis, census tract income, stage at
diagnosis, ER status, and the number of hospitals with oncology services in the area of residence.
However, for the SEER-Medicare cohort, median time period for treatment was significantly
different for all the variables except mental health condition and number of hospitals with
oncology services in the area of residence.
Proportion of Study Cohorts Receiving Timely Diagnosis and Treatment as Per the
Published Recommendations
Figure 3.2 summarizes the proportion of the study cohorts who received timely BC
diagnosis of BC as per the published opinion-based recommendations. Approximately only 63%
of women in the WV-Medicare cohort received timely diagnosis of BC as compared to 71% of
the SEER-Medicare cohort. Figure 3.3 summarizes the proportion of the study cohorts who
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received timely treatment of BC as per the published opinion-based recommendations. Seventysix percent of the WV-Medicare cohort received timely BC treatment as compared to 73% of the
SEER-Medicare cohort.
Factors Associated with Timely Diagnosis and Timely Treatment
Table 3.5 describes the factors associated with timely diagnosis and timely treatment as
per the published opinion-based recommendations for both the study cohorts. For the WVMedicare cohort, higher census tract household income above $35,000 (AOR=3.33, 95%
CI=1.41-7.83) and tumor size > 3 cm was significantly associated with timely diagnosis of BC.
While for the SEER-Medicare cohort, age 80 and above, white race (AOR=1.21, 95% CI=1.121.30), non-metro residence (AOR=1.30, 95% CI=1.20-1.40), higher census tract education
(AOR=1.07, 95% CI=1.01-1.14), distant stage of BC, moderately (AOR=1.09, 95% CI=1.021.16) and poorly (AOR=1.26, 95% CI=1.17-1.36) differentiated grade of tumor, tumor size > 3
cm, no comorbidity and low PCP visits were significantly associated with timely diagnosis of
BC. Surprisingly, no factors were significantly associated with timely treatment of BC for the
WV-Medicare cohort. However, for the SEER-Medicare cohort, age 66 to 74 years, white race
(AOR=1.36, 95% CI=1.26-1.47), non-metro residence (AOR=1.28, 95% CI=1.18-1.39), earlier
stages of BC, tumor size < 3 cm, no comorbidity, high PCP visits (AOR=1.06, 95% CI=1.011.12), and low hospitals with oncology services in the area of residence were significantly
associated with timely treatment of BC.
Differences in Timely Diagnosis and Treatment between Study Cohorts in a Multivariate
Framework
Table 3.6 summarizes the results for timely diagnosis and timely treatment, to identify
any significant differences in timeliness between WV-Medicare and SEER-Medicare study

68

cohorts. As compared to the SEER-Medicare cohort, the WV-Medicare cohort was significantly
less likely to receive timely diagnosis of BC (AOR=0.76, 95% CI=0.64-0.90), but it was equally
likely as the SEER-Medicare cohort to receive timely treatment of BC (AOR=1.00, 95%
CI=0.83-1.23).
Differences in Survival between Study Cohorts with Receipt of Timely Diagnosis and
Timely Treatment in a Multivariate Framework
Table 3.7 summarizes the results on probabilities of survival with receipt of timely
clinical BC care, to identify any significant differences between WV-Medicare and SEERMedicare study cohorts. As compared to the SEER-Medicare cohort, the WV-Medicare cohort
was significantly more likely to be alive at the follow-up period of three years.
DISCUSSION
In the Institute of Medicine’s report Crossing the Quality Chasm, six constructs of
healthcare quality are defined 46,47, out of which timeliness of care is one of the most important
aspects of measuring quality of cancer care 48. Delays in diagnosis and treatment in BC patients
lead to high emotional distress in patients 6-8,49, and also poor health outcomes in terms of
compromised survival 9. Previous studies which evaluated timeliness of BC care in elderly BC
patients using nationally representative populations did not use any published recommendations
to define timely BC care 16-24. This is the first study to identify differences in timeliness of BC
care (diagnosis, treatment) as per the published opinion-based recommendations from EUSOMA
and NICE in elderly women with BC in a rural state such as WV and a nationally representative
population from the SEER-Medicare data, and to determine the factors associated with timely
BC care in these study cohorts. The study findings indicate that the two study cohorts were
statistically different in terms of most of their characteristics. The median number of days for
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BC diagnosis was higher in WV-Medicare cohort as compared to that from the SEER-Medicare
cohort. In addition, WV-Medicare cohort was significantly less likely to receive timely
diagnosis of BC as compared to the SEER-Medicare cohort after controlling for all the factors.
This difference of timely BC diagnosis between the WV-Medicare and SEER-Medicare cohorts
may be a reflection of WV women’s social and cultural barriers in form of psychosocial factors
such as fear, sense of fatalism, knowledge and beliefs, perceived risk, social norms, physicians’
characteristics, and health system factors such as cultural variations in BC detection and followup, or preferences in cancer detection 19,50-56 which are not measured in this study. Future
studies may assess the effects of these factors that may contribute to diagnosis delays in this rural
state. Efforts to expedite diagnostic evaluations after any breast abnormality and abnormality in
screenings may help reduce untimely BC diagnosis in elderly WV women.
Among the predictors of timely BC diagnosis, higher annual household income was
significantly associated with timely diagnosis of BC in the WV-Medicare cohort. This finding
was consistent with the previous studies which identified association between lower income and
delayed BC diagnosis 57-59. Again consistent with previous studies, WV women with tumor size
less than 1 cm was associated with delayed BC diagnosis as compared to women with tumor size
greater than 3 cm, thereby emphasizing the prompt evaluation of women with large volume of
tumors 16,60-62.
The median days for initiation of BC treatment after diagnosis was lower in WV women
as compared to those from the SEER-Medicare data. This finding is consistent with previous
studies 16,63 in which the authors argued that rural women who may have to travel longer
distances for evaluations and treatments might well be referred for treatment on that same day to
minimize travel 63. Also, the median days from initiation of surgery, chemotherapy or radiation
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therapy did not vary much by stage at BC diagnosis for both the study cohorts. Within women
who have had surgery as their first BC treatment, those with regional and local stage cancers had
higher median days of treatment for the WV-Medicare cohort. Within those who had
chemotherapy as their first BC treatment, women with distant cancer had lowest median days for
the WV-Medicare cohort. Furthermore, there were no significant differences in timely treatment
of BC between WV-Medicare and SEER-Medicare cohorts after controlling for all the factors.
This indicates that rural and low income population in a state such as WV is equally likely to
receive timely BC treatment as the SEER-Medicare population. This finding is remarkable since
rural settings are less likely to have specialized equipment or trained healthcare professionals 64.
An interesting finding of this study is that there were no significant predictors of timely BC
treatment in the WV-Medicare cohort thereby indicating that several unmeasured factors such as
health status, body mass index (BMI), psychosocial factors such as fear, fatalism, knowledge and
beliefs, and health system factors may be affecting timely BC treatment in these rural WV
women.
Finally, it was found that WV-Medicare cohort had surprisingly higher probability of
being alive at the end of the follow-up period of three years after controlling for timeliness of BC
care. Given the prognosis of the disease and higher five-years survival in women with BC 3, the
follow-up period of three years to model probability of being alive in elderly women who receive
timely BC care may not generate robust statistical estimates for this association to make any
conclusions in this regards. Future studies to assess the effect of timely BC care in elderly
women with BC on survival and how it varies between the rural setting and the national
population, may require a longer follow-up period of at least five to ten years to generate robust
conclusions.
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This study’s interpretation is limited by the nature of the cancer registry-Medicare linked
dataset. Since administrative claims were utilized for the analyses of timeliness of BC care, any
healthcare services received outside of the Medicare settings may not be captured which may
affect the precision of the estimates. Also, these data could only identify procedures and
diagnoses that healthcare providers include on billings on the dates of services and hence could
not determine types of BC symptoms or the sequence of procedures occurred on the same date.
For instance, if the diagnostic mammography and MRI had the same claim date for a particular
woman then it was not possible to identify which procedure occurred first. In addition, the
typical sequence of events which leads to BC diagnosis depends on whether the abnormality in
the breast was first detected by the patient, or the clinician, or through the screening
mammogram 19. Since this study utilized administrative claims data, whether diagnosis of BC
was affected by patient-related factors (patient delay) or system-related factors (structural delay)
was not identified and hence was not controlled in the analyses. Adjuvant therapy with
prescription drugs was not captured in the analyses as these were not covered by Medicare prior
to 2007. Several important variables such as annual household income, education level, access
to BC screening centers and hospitals offering oncology services are not available in the cancer
registries-Medicare linked databases and hence census tract information for these variables were
utilized 65. Data on some important variables which may affect timeliness of BC care such as
health status, severity of comorbidities, and patient preferences were not available. This study
included individuals who received BC treatment in the form of surgery, radiation, and
chemotherapy within one year after diagnosis and hence the findings cannot be generalized to
individuals who do not receive any treatment. As this study is based on observational data, the
study findings cannot establish causality. In addition, the findings of this study are only
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generalizable to elderly BC patients covered only by Medicare. Also, the findings are not
generalizable to other rural populations. Despite these limitations, this study provides important
inputs on the timeliness of BC care and associated health outcomes in a BC population that is
aged, belongs to a lower socio-economic status, and from a rural state such as WV.
CONCLUSION
Timely BC diagnosis is a critical concern in a rural state such as WV as women in this
state are less likely to get timely BC diagnosis when compared to their national counterparts,
however the chances of their survival are higher. Interventions that address patient, provider and
health system factors which contribute to delay in BC diagnosis in WV are needed to be
developed and implemented to achieve timely BC diagnosis.
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Table 3.1
Description of the Study Cohorts
2003-2006
WV-Medicare
(N=1,388)

Variables

N
Age at Diagnosis
66-69
70-74
75-79
80,+
Race
White
Other
Location of Residence
Metro
Non-metro
Census Tract Household Income
LE $35,000
GT $35,000
Census Tract Education
LT 15% pop. with CE
GE 15% pop. with CE
Stage at Diagnosis
Insitu
Local
Regional
Distant
Grade of Tumor
Well Differentiated
Moderately Differentiated
Poorly Differentiated
Undifferentiated/Unknown
ER Status
Positive
Negative
Borderline/Unknown
Tumor Size
<1 cm
1-2 cm
2-3 cm
>3 cm
Comorbidity
0
1
2,+
Mental Condition
Yes
No
PCP visits
High
Low

SEER-Medicare
(N=36,276)
%

N

%

275
385
379
349

19.8
27.7
27.3
25.1

7,975
9,079
8,624
10,598

22.0
25.0
23.8
29.2

1,355
33

97.6
2.4

32,124
4,152

88.6
11.4

762
626

54.9
45.1

30,349
5,927

83.7
16.3

1,268
120

91.4
8.6

8,949
27,327

24.7
75.3

704
684

50.7
49.3

11,005
25,271

30.3
69.7

209
866
274
38

15.1
62.4
19.8
2.7

5,982
20,982
8,166
1,146

16.5
57.8
22.5
3.2

325
473
306
284

23.4
34.1
22.0
20.5

7,762
14,258
9,252
5,004

21.4
39.3
25.5
13.8

628
126
634

45.2
9.1
45.7

25,018
5,114
6,144

69.0
14.1
16.9

290
409
158
126

29.5
41.6
16.1
12.8

7,992
13,809
5,485
7,999

22.6
39.1
15.5
22.7

716
416
256

51.6
30.0
18.4

20,890
9,796
5,590

57.6
27.0
15.4

134
1,254

9.7
90.3

2,256
34,020

6.2
93.8

689
699

49.6
50.4

17,851
49.2
18,425
50.8
(Continued)…

Sig
***

***

***

***

***

*

***

***

***

***

***
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Table 3.1
Description of the Study Cohorts
2003-2006
WV-Medicare
(N=1,388)

Variables

N

Total BC Screening Centers
High
Low
Total Hospitals with Oncology Services
High
Low

SEER-Medicare
(N=36,276)
%

N

%

Sig

***
587
801

42.3
57.7

17,714
18,562

48.8
51.2

551
837

39.7
60.3

16,157
20,119

44.5
55.5

***

Note: Based on 1,388 elderly WV-Medicare women and 36,276 elderly SEER-Medicare women, age 66 and above diagnosed
with primary incident breast cancer from 2003 to 2006. FFS, Fee-for-service; WV, West Virginia; SEER, Surveillance,
Epidemiology, and End Results; ER, Estrogen-receptor; PCP, Primary Care Physicians, BC, Breast Cancer; CE, College
Education; pop., population; LE, Less than or equal to; GT, Greater than; LT, Less than; GE, Greater than or equal to; Sig,
Significance. Asterisks represent statistically significant group differences based on χ2 tests: ***P<0.001; **001<=P<.01 ;
*.01<=P<.05.

Table 3.2
Median Days in Diagnosis and Treatment for the Study Cohorts
2003-2006

Type of Delay
N

WV-Medicare (N=1,388)
Median
25-75% IQR
(Days)
(Days)

SEER-Medicare (N=36,276)
Median
25-75% IQR
N
(Days)
(Days)

Initial Consultation to Diagnosis

892

26

12 to 50

35,717

20

8 to 41

Diagnosis to Treatment

851

8

0 to 28

34,695

15

0 to 29

738

0

0 to 25

31,779

14

0 to 28

Diagnosis to Chemotherapy

39

20

15 to 29

1,329

25

14 to 45

Diagnosis to Radiation

74

27

16 to 48

1,587

28

15 to 49

Diagnosis to Surgery

Note: Based on 1,388 elderly WV-Medicare women and 36,276 elderly SEER-Medicare women, age 66 and above diagnosed
with primary incident breast cancer from 2003 to 2006. WV, West Virginia; SEER, Surveillance, Epidemiology, and End
Results; IQR, Inter Quartile Range.
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Table 3.3
Median Days (IQR) for Type of Initial Treatment by Stage at Diagnosis
For the Study Cohorts
2003-2006

WV-Medicare
Diagnosis to
Surgery

SEER-Medicare
Diagnosis to
Surgery

WV-Medicare
Diagnosis to
Chemotherapy

SEER-Medicare
Diagnosis to
Chemotherapy

WV-Medicare
Diagnosis to
Radiation

SEER-Medicare
Diagnosis to
Radiation

Insitu

0 (0 to 20)

11 (0 to 28)

178 (178 to 178)

21 (8 to 34)

31 (24 to 64)

28 (19 to 46)

Local

0 (0 to 26)

14 (0 to 28)

20 (15 to 51)

29 (15 to 50)

27 (16 to 48)

30 (17 to 49)

Regional

9 (0 to 25)

15 (0 to 29)

21 (11 to 27)

25 (14 to 42)

17 (14 to 55)

29 (15 to 54)

Distant

10 (0 to 24)

14 (0 to 29)

17 (15 to 31)

24 (14 to 49)

25 (4 to 44)

13 (4 to 42)

Stage at
Diagnosis

Note: Based on 1,388 elderly WV-Medicare women and 36,276 elderly SEER-Medicare women, age 66 and above diagnosed
with primary incident breast cancer from 2003 to 2006. WV, West Virginia; SEER, Surveillance, Epidemiology, and End
Results; IQR, Inter Quartile Range.
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Table 3.4
Median Days in Diagnosis and Treatment within Independent Variables for the Study Cohorts
2003-2006

Initial Consultation to Diagnosis
Variables

WV-Medicare
Median
N
(IQR)
892

Age at Diagnosis

SEER-Medicare
Median
N
(IQR)

Diagnosis to Treatment
WV-Medicare
Median
N
(IQR)

35,717

851

34,695

***

**

***

66-69

167

27 (13 to 50)

7,827

21 (9 to 43)

170

70-74

245

27 (12 to 55)

8,961

21 (9 to 42)

75-79

238

26 (13 to 49)

8,496

21 (9 to 41)

80,+

242

22 (8 to 44)

10,433

18 (7 to 37)

Race

SEER-Medicare
Median
N
(IQR)

8 (0 to 28)

7,825

14 (0 to 28)

239

0 (0 to 23)

8,863

15 (0 to 29)

226

10 (0 to 31)

8,337

15 (0 to 30)

216

14 (0 to 32)

9,670

16 (0 to 32)

***

***

White

876

26 (12 to 49)

31,639

20 (8 to 41)

835

8 (0 to 28)

30,796

15 (0 to 29)

Other

16

20 (8 to 53)

4,078

22 (9 to 47)

16

16 (0 to 34)

3,899

19 (0 to 36)

Location of Residence

***

***

Metro

469

27 (13 to 51)

29,901

21 (8 to 42)

444

9 (0 to 28)

Non-metro

423

24 (11 to 48)

5,816

18 (8 to 36)

407

7 (0 to 28)

Census Tract Household Income

**

29,045

16 (0 to 31)

5,650

12 (0 to 25)

**

LE $35,000

817

26 (12 to 51)

8,775

20 (8 to 41)

779

6 (0 to 27)

8,447

14 (0 to 29)

GT $35,000

75

24 (10 to 38)

26,942

20 (8 to 41)

72

17 (0 to 36)

26,248

15 (0 to 30)

Census Tract Education
LT 15% pop.
with CE
456
GE 15% pop.
with CE
436

***
26 (12 to 52)

10,822

20 (9 to 42)

441

10 (0 to 30)

10,463

14 (0 to 29)

27 (11 to 48)

24,895

20 (8 to 41)

410

6 (0 to 25)

24,232

16 (0 to 30)

Stage at Diagnosis

***

Insitu

151

35 (20 to 64)

5,904

28 (14 to 58)

144

0 (0 to 27)

5,705

12 (0 to 28)

Local

553

27 (13 to 51)

20,797

21 (9 to 41)

525

9 (0 to 29)

20,209

15 (0 to 29)

Regional

164

17 (8 to 37)

8,029

16 (6 to 34)

162

11 (0 to 26)

7,883

17 (0 to 31)

23

7 (4 to 17)

987

7 (1 to 21)

19

17 (4 to 41)

898

18 (6 to 37)

Distant
Grade of Tumor

***

**

*

***

***

***

Well D

204

29 (15 to 54)

7,695

22 (10 to 44)

194

0 (0 to 29)

7,505

15 (0 to 29)

Moderately D

302

24 (11 to 50)

14,074

20 (8 to 40)

295

9 (0 to 29)

13,735

15 (0 to 30)

Poorly D
Undifferentiated
/Unknown

191

20 (8 to 43)

9,098

17 (7 to 35)

189

10 (0 to 26)

8,993

16 (0 to 29)

195

28 (15 to 55)

4,850

23 (10 to 51)

173

11 (0 to 31)

4,462

14 (0 to 29)

389

24 (10 to 48)

24,664

20 (8 to 40)

365

13 (0 to 30)

24,080

15 (0 to 30)

78

23 (10 to 41)

5,022

17 (7 to 36)

77

9 (0 to 22)

4,996

16 (0 to 30)

425

27 (13 to 52)

6,031

25 (11 to 50)

409

0 (0 to 28)

5,619

13 (0 to 29)

ER Status
Positive
Negative
Borderline/Unkn
own

***

*

***

(Continued)…
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Table 3.4
Median Days in Diagnosis and Treatment within Independent Variables for the Study Cohorts
2003-2006

Initial Consultation to Diagnosis
Variables

WV-Medicare
Median
N
(IQR)

SEER-Medicare
Median
N
(IQR)

Diagnosis to Treatment
WV-Medicare
Median
N
(IQR)

892

35,717

Tumor Size

***

***

<1 cm

191

29 (17 to 49)

7,921

26 (12 to 52)

185

0 (0 to 31)

7,824

13 (0 to 28)

1-2 cm

255

26 (10 to 48)

13,675

20 (8 to 39)

240

14 (0 to 29)

13,379

14 (0 to 29)

2-3 cm

99

19 (8 to 44)

5,430

16 (7 to 34)

90

12 (0 to 28)

5,279

16 (0 to 30)

>3 cm

75

13 (4 to 29)

7,753

17 (6 to 38)

72

12 (0 to 25)

7,341

17 (0 to 32)

Comorbidity

851

SEER-Medicare
Median
N
(IQR)
34,695
***

***

***

0

458

24 (12 to 47)

20,550

20 (8 to 40)

438

5 (0 to 28)

20,111

15 (0 to 29)

1

268

27 (10 to 49)

9,650

21 (9 to 42)

265

10 (0 to 29)

9,361

15 (0 to 29)

2,+

166

29 (13 to 60)

5,517

22 (9 to 45)

148

9 (0 to 29)

5,223

17 (0 to 33)

Mental Condition

*

Yes

87

23 (11 to 49)

2,227

21 (9 to 42)

83

9 (0 to 28)

2,104

14 (0 to 29)

No

805

26 (12 to 50)

33,490

20 (8 to 41)

768

7 (0 to 28)

32,591

15 (0 to 29)

PCP visits

***

***

High

455

27 (12 to 53)

17,635

22 (10 to 45)

430

7 (0 to 28)

17,004

15 (0 to 29)

Low

437

25 (11 to 48)

18,082

19 (7 to 37)

421

9 (0 to 28)

17,691

15 (0 to 30)

27 (13 to 52)

17,449

21 (8 to 42)

353

2 (0 to 22)

16,929

18 (0 to 33)

Low
518 26 (11 to 48)
Total Hospitals with Oncology Services

18,268

20 (8 to 40)

498

13 (0 to 32)

17,766

13 (0 to 27)

Total BC Screening Centers
High

374

**

***

***

**

High

351

27 (12 to 51)

15,924

21 (8 to 43)

330

1 (0 to 23)

15,427

19 (0 to 33)

Low

541

26 (12 to 48)

19,793

20 (8 to 40)

521

13 (0 to 31)

19,268

13 (0 to 27)

Note: Based on 1,388 elderly WV-Medicare women and 36,276 elderly SEER-Medicare women, age 66 and above diagnosed
with primary incident breast cancer from 2003 to 2006. WV, West Virginia; SEER, Surveillance, Epidemiology, and End
Results; CE, College Education; pop., population; D, Differentiated; ER, Estrogen-receptor; PCP, Primary Care Physicians, BC,
Breast Cancer; LE, Less than or equal to; GT, Greater than; LT, Less than; GE, Greater than or equal to; IQR, Inter Quartile
Range; Sig, Significance. Asterisks represent statistically significant group differences based on Kruskal-Wallis tests:
***P<0.001; **001<=P<.01 ; *.01<=P<.05.

86

Table 3.5
Factors Associated with Timely Diagnosis and Timely Treatment Separately for the Study Cohorts
Adjusted Odds Ratios and 95% Confidence Intervals from Logistic Regressions
2003-2006

Variables

WV-Medicare

SEER-Medicare

WV-Medicare

SEER-Medicare

Timely Diagnosis

Timely Diagnosis

Timely Treatment

Timely Treatment

Model 1

Model 2

Model 3

Model 4

AOR

95% CI

66-69

0.98

[0.59,1.64]

70-74

0.79

75-79

0.88

Sig

AOR

95% CI

Sig

AOR

95% CI

0.81

[0.76,0.87]

***

1.55

[0.87,2.77]

[0.49,1.28]

0.83

[0.78,0.89]

***

1.72

[0.54,1.42]

0.87

[0.81,0.93]

***

1.07

Sig

AOR

95% CI

Sig

1.23

[1.14,1.32]

***

[0.99,3.01]

1.17

[1.09,1.25]

***

[0.63,1.80]

1.07

[1.00,1.14]

*

[1.26,1.47]

***

[1.18,1.39]

***

Age at Diagnosis

80,+

1

1

1

1

Race
White

1.31

Other

1

[0.25,6.75]

1.21
1

[1.12,1.30]

1

1

1

1

1

1

***

0.91

[0.09,8.84]

1.36

Location of Residence
Metro
Non-metro

1.40

[0.91,2.17]

1.30

[1.20,1.40]

***

1.47

[0.90,2.40]

1.28

Census Tract Household Income
LE $35,000

1

GT $35,000

3.33

1
[1.41,7.83]

**

1.03

1
[0.96,1.10]

0.77

1
[0.33,1.80]

1.07

[1.00,1.15]

Census Tract Education
LT 15% pop. with CE

1

GE 15% pop. with CE

0.77

[0.48,1.22]

1.07

[1.01,1.14]

*

1.45

[0.84,2.52]

0.94

[0.88,1.00]

*

Insitu

0.19

[0.02,1.57]

0.33

[0.27,0.39]

***

0.74

[0.14,4.02]

1.37

[1.17,1.61]

***

Local

0.23

[0.03,1.86]

0.51

[0.42,0.61]

***

0.76

[0.15,3.77]

1.23

[1.05,1.43]

**

Regional

0.28

[0.03,2.28]

0.60

[0.50,0.73]

***

0.91

[0.18,4.71]

1.19

[1.02,1.38]

*

1

1

1

Stage at Diagnosis

Distant

1

1

1

1
(Continued)…
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Table 3.5
Factors Associated with Timely Diagnosis and Timely Treatment Separately for the Study Cohorts
Adjusted Odds Ratios and 95% Confidence Intervals from Logistic Regressions
2003-2006

Variables
AOR

WV-Medicare

SEER-Medicare

WV-Medicare

SEER-Medicare

Timely Diagnosis

Timely Diagnosis

Timely Treatment

Timely Treatment

Model 1

Model 2

Model 3

Model 4

95% CI

Sig

AOR

95% CI

Sig

AOR

95% CI

Sig

AOR

95% CI

Sig

Grade of Tumor
Well D

1

1

1

Moderately D

1.34

[0.85,2.11

1.09

[1.02,1.16]

Poorly D

1.32

[0.77,2.26]

1.26

[1.17,1.36]

Undifferentiated/Unknown

0.94

[0.54,1.65]

0.93

1

**

1.07

[0.64,1.78]

0.98

[0.92,1.05]

***

1.33

[0.71,2.49]

1.04

[0.96,1.12]

[0.85,1.01]

1.18

[0.62,2.23]

1.00

[0.91,1.10]

1.95

[0.88,4.32]

1.02

[0.95,1.10]

ER Status
Positive

1

1

1

1

Negative

0.97

[0.52,1.78]

1.01

[0.94,1.09]

Borderline/Unknown

1.22

[0.80,1.87]

0.85

[0.79,0.91]

***

1.11

[0.70,1.78]

1.07

[0.99,1.16]

<1 cm

0.48

[0.23,0.97]

0.66

[0.61,0.71]

***

0.59

[0.27,1.31]

1.22

[1.13,1.32]

***

1-2 cm

0.58

[0.30,1.12]

0.90

[0.84,0.96]

**

0.63

[0.30,1.34]

1.20

[1.12,1.29]

***

2-3 cm

0.60

[0.29,1.24]

1.06

[0.98,1.16]

0.66

[0.29,1.51]

1.12

[1.03,1.21]

**

>3 cm

1

Tumor Size
*

1

1

1

Comorbidity
0

1

1

0.72

[0.48,1.08]

0.93

[0.88,0.98]

**

0.67

[0.43,1.05]

0.96

[0.90,1.02]

2,+

0.65

[0.41,1.04]

0.84

[0.78,0.90]

***

0.92

[0.53,1.60]

0.81

[0.76,0.88]

1.16

[0.65,2.08]

0.99

[0.90,1.10]

1.05

[0.54,2.02]

1.07

[0.96,1.19]

1

1

1

Mental Condition
Yes
No

1

1

1

1
(Continued)…
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***

Table 3.5
Factors Associated with Timely Diagnosis and Timely Treatment Separately for the Study Cohorts
Adjusted Odds Ratios and 95% Confidence Intervals from Logistic Regressions
2003-2006

Variables

WV-Medicare

SEER-Medicare

WV-Medicare

SEER-Medicare

Timely Diagnosis

Timely Diagnosis

Timely Treatment

Timely Treatment

Model 1

Model 2

Model 3

Model 4

AOR

95% CI

High

0.84

[0.59,1.21]

Low

1

Sig

AOR

95% CI

Sig

[0.73,0.81]

***

AOR

95% CI

Sig

AOR

95% CI

Sig

[1.01,1.12]

*

PCP visits
0.77

1.05

1

[0.70,1.57]

1.06

1

1

Total BC Screening Centers
High

0.93

Low

1

[0.58,1.50]

0.98

[0.93,1.03]

1

NA

NA

NA

NA

NA

NA

NA

NA

Total Hospitals with Oncology Services
High

NA

NA

NA

NA

1.50

Low

NA

NA

NA

NA

1

[0.84,2.68]

0.71

[0.67,0.75]

***

1

Note: Based on 1,388 elderly WV-Medicare women and 36,276 elderly SEER-Medicare women, age 66 and above diagnosed with primary incident breast cancer from 2003 to
2006. WV, West Virginia; SEER, Surveillance, Epidemiology, and End Results; CE, College Education; pop., population; D, Differentiated; ER, Estrogen-receptor; PCP, Primary
Care Physicians, BC, Breast Cancer; LE, Less than or equal to; GT, Greater than; LT, Less than; GE, Greater than or equal to; AOR, Adjusted Odds Ratio; CI, Confidence
Interval; Sig, Significance; NA, Not Applicable. The regressions also include intercept terms and parameter estimates for other variable controlled are not presented. Model 1
represents Timely Care from Initial Consultation to Diagnosis for WV-Medicare cohort; Model 2 represents Timely Care from Initial Consultation to Diagnosis for SEERMedicare cohort; Model 3 represents Timely Care from Diagnosis to Treatment for WV-Medicare cohort; Model 4 represents Timely Care from Diagnosis to Treatment for SEERMedicare cohort. "Non-timely care for Diagnosis", was the reference group for Models 1 and 2 for respective cohorts for the dependent variable, and "Non-timely care for
Treatment" was the reference group for Models 3 and 4 for respective cohorts for the dependent variable. Asterisks represent statistically significant group differences compared
with the reference group: ***P<0.001; **001<=P<.01 ; *.01<=P<.05.
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Table 3.6
Differences in Timely Diagnosis and Treatment between Study Cohorts
In a Multivariate Framework
Adjusted Odds Ratios and 95% Confidence Intervals from Logistic Regressions
2003-2006
WV-Medicare
Timely Diagnosis

Timely Treatment

Model 1

Model 2

Variables
AOR

95% CI

Sig

[0.64,0.90]

**

AOR

95% CI

Sig

Type of Setting
WV-Medicare
SEER-Medicare

0.76
1

1.00

[0.82,1.22]

1

Age at Diagnosis
66-69

0.82

[0.76,0.87]

***

1.23

[1.15,1.32]

***

70-74

0.83

[0.78,0.89]

***

1.18

[1.10,1.26]

***

75-79

0.87

[0.81,0.93]

***

1.07

[1.00,1.14]

80,+

1

1

Race
White

1.21

[1.12,1.30]

Other

1

1

1

1

***

1.37

[1.27,1.48]

***

[1.18,1.38]

***

Location of Residence
Metro
Non-metro

1.31

[1.21,1.41]

***

1.27

Census Tract Household Income
LE $35,000

1

GT $35,000

1.05

1
[0.98,1.12]

1.05

[0.98,1.13]

Census Tract Education
LT 15% pop. with CE

1

GE 15% pop. with CE

1.06

[1.00,1.13]

Insitu

0.32

[0.27,0.39]

Local

0.50

Regional

0.60

1
0.95

[0.90,1.01]

***

1.36

[1.16,1.60]

***

[0.42,0.60]

***

1.22

[1.05,1.42]

*

[0.50,0.72]

***

1.18

[1.02,1.38]

*

Stage at Diagnosis

Distant

1

1

1

1

Grade of Tumor
Well Differentiated
Moderately Differentiated

1.09

[1.03,1.16]

**

0.99

[0.92,1.05]

Poorly Differentiated

1.26

[1.17,1.36]

***

1.04

[0.96,1.12]

Undifferentiated/Unknown

0.92

[0.85,1.01]

1.00

[0.91,1.10]

(Continued)…
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Table 3.6
Differences in Timely Diagnosis and Treatment between Study Cohorts
In a Multivariate Framework
Adjusted Odds Ratios and 95% Confidence Intervals from Logistic Regressions
2003-2006
WV-Medicare
Timely Diagnosis

Timely Treatment

Model 1

Model 2

Variables
AOR

95% CI

Sig

AOR

95% CI

Sig

ER Status
Positive

1

1

Negative

1.01

[0.94,1.09]

1.03

[0.95,1.11]

Borderline/Unknown

0.86

[0.81,0.92]

***

1.07

[0.99,1.15]

<1 cm

0.66

[0.62,0.71]

***

1.21

[1.12,1.31]

***

1-2 cm

0.90

[0.84,0.96]

**

1.19

[1.11,1.28]

***

2-3 cm

1.06

[0.97,1.15]

1.11

[1.02,1.20]

*

>3 cm

1

1

0

1

1

1

0.92

[0.88,0.98]

2,+

0.83

[0.78,0.89]

1.00

[0.91,1.10]

Tumor Size

Comorbidity
**

0.96

[0.90,1.01]

***

0.82

[0.76,0.88]

1.07

[0.96,1.18]

***

Mental Condition
Yes
No

1

1

PCP visits
High

0.77

Low

1

[0.74,0.81]

***

1.06

[1.01,1.12]

*

1

Total BC Screening Centers
High

0.97

Low

1

[0.92,1.02]

**

NA

NA

NA

NA

Total Hospitals with Oncology Services
High

NA

NA

0.72

Low

NA

NA

1

[0.68,0.76]

***

Note: Based on 1,388 elderly WV-Medicare women and 36,276 elderly SEER-Medicare women, age 66 and above diagnosed
with primary incident breast cancer from 2003 to 2006. WV, West Virginia; SEER, Surveillance, Epidemiology, and End
Results; CE, College Education; pop., population; D, Differentiated; ER, Estrogen-receptor; PCP, Primary Care Physicians, BC,
Breast Cancer; LE, Less than or equal to; GT, Greater than; LT, Less than; GE, Greater than or equal to; AOR, Adjusted Odds
Ratio; CI, Confidence Interval; Sig, Significance; NA, Not Applicable. The regressions also include intercept terms and
parameter estimates for other variable controlled are not presented. Model 1 represents Timely Care from Initial Consultation to
Diagnosis; Model 2 represents Timely Care from Diagnosis to Treatment. "Non-timely care for Diagnosis" and "Non-timely care
for Treatment" are the reference groups for Model 1 and Model 2, respectively for the dependent variables. Asterisks represent
statistically significant group differences compared with the reference group: ***P<0.001; **001<=P<.01 ; *.01<=P<.05
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Table 3.7
Differences in Survival between Study Cohorts with Receipt of Timely Diagnosis and Timely Treatment in a Multivariate Framework
Adjusted Odds Ratios and 95% Confidence Intervals from Logistic Regressions
2003-2006
WV-Medicare
Variables

Model 1
AOR

Model 2

95% CI

Sig

[3.33,18.20]

***

AOR

95% CI

Sig

[2.89,16.1]

***

Type of Setting
WV-Medicare
SEER-Medicare

7.79
1

6.82
1

Timely Diagnosis
Yes
No

0.91

[0.81,1.02]

1

NA

NA

NA

NA
[1.04,1.31]

*

Timely Treatment
Yes

NA

NA

1.17

No

NA

NA

1

66-69

5.06

[4.27,6.00]

***

4.55

[3.83,5.40]

***

70-74

3.10

[2.70,3.56]

***

2.87

[2.49,3.31]

***

75-79

2.45

[2.15,2.80]

***

2.29

[2.00,2.62]

***

Age at Diagnosis

80,+

1

1

Race
White

0.95

Other

1

[0.81,1.12]

0.95

[0.80,1.12]

1

Location of Residence
Metro
Non-metro

1
0.99

1
[0.85,1.16]

1.01

[0.86,1.19]

Census Tract Household Income
LE $35,000

1

GT $35,000

1.07

1
[0.93,1.22]

1.07

[0.92,1.23]
(Continued)…

92

Table 3.7
Differences in Survival between Study Cohorts with Receipt of Timely Diagnosis and Timely Treatment in a Multivariate Framework
Adjusted Odds Ratios and 95% Confidence Intervals from Logistic Regressions
2003-2006
WV-Medicare
Variables

Model 1
AOR

Model 2

95% CI

Sig

AOR

95% CI

Sig

Census Tract Education
LT 15% pop. with CE

1

GE 15% pop. with CE

1.20

[1.06,1.35]

**

1.19

[1.05,1.36]

*

Insitu

34.91

[25.5,47.6]

***

34.75

[25.0,48.1]

***

Local

11.07

[8.72,14.0]

***

11.13

[8.72,14.2]

***

6.56

[5.18,8.31]

***

6.20

[4.87,7.89]

***

1

Stage at Diagnosis

Regional
Distant

1

1

1

1

Grade of Tumor
Well D
Moderately D

0.87

[0.74,1.02]

0.84

[0.71,0.99]

*

Poorly D

0.61

[0.51,0.72]

***

0.58

[0.48,0.69]

***

Undifferentiated/Unknown

0.73

[0.60,0.89]

**

0.80

[0.65,1.00]

*

ER Status
Positive

1

1

Negative

0.49

[0.43,0.57]

***

0.49

[0.43,0.57]

***

Borderline/Unknown

0.74

[0.64,0.86]

***

0.81

[0.69,0.94]

**

<1 cm

2.85

[2.38,3.42]

***

2.67

[2.22,3.22]

***

1-2 cm

2.30

[2.01,2.63]

***

2.35

[2.04,2.70]

***

2-3 cm

1.50

[1.30,1.74]

***

1.49

[1.29,1.73]

***

>3 cm

1

Tumor Size

1
(Continued)…
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Table 3.7
Differences in Survival between Study Cohorts with Receipt of Timely Diagnosis and Timely Treatment in a Multivariate Framework
Adjusted Odds Ratios and 95% Confidence Intervals from Logistic Regressions
2003-2006
WV-Medicare
Variables

Model 1
AOR

Model 2

95% CI

Sig

AOR

95% CI

Sig

Comorbidity
0

1

1

0.64

[0.57,0.72]

***

0.64

[0.56,0.73]

***

2,+

0.36

[0.32,0.41]

***

0.37

[0.32,0.42]

***

0.64

[0.53,0.77]

***

0.70

[0.58,0.85]

***

[0.78,0.97]

**

1

Mental Condition
Yes
No

1

1

PCP visits
High

0.84

Low

1

[0.75,0.93]

**

0.87
1

Total Hospitals with BC Screening Services
High

1.03

Low

1

[0.92,1.16]

NA

NA

NA

NA

Total Hospitals with Oncology Services
High

NA

NA

1.12

Low

NA

NA

1

[1.00,1.26]

Note: Based on 1,388 elderly WV-Medicare women and 36,276 elderly SEER-Medicare women, age 66 and above diagnosed with primary incident breast cancer from 2003 to
2006. WV, West Virginia; SEER, Surveillance, Epidemiology, and End Results; CE, College Education; pop., population; D, Differentiated; ER, Estrogen-receptor; PCP, Primary
Care Physicians, BC, Breast Cancer; LE, Less than or equal to; GT, Greater than; LT, Less than; GE, Greater than or equal to; NA, Not Applicable; AOR, Adjusted Odds Ratio;
CI, Confidence Interval; Sig, Significance. The regressions also include intercept terms and parameter estimates for other variable controlled are not presented. Model 1 represents
Survival After Controlling for Timely Diagnosis; Model 2 represents Survival after Controlling for Timely Treatment. "Death" is the reference group for the dependent variables
for both the models. Asterisks represent statistically significant group differences compared with the reference group: ***P<0.001; **001<=P<.01 ; *.01<=P<.05.
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CHAPTER 4
TOTAL HEALTHCARE COSTS AMONG ELDERLY WOMEN WITH BREAST
CANCER IN THE INITIAL PERIOD OF ONE YEAR AFTER DIAGNOSIS: AN
APPLICATION OF DECOMPOSITION TECHNIQUE
INTRODUCTION
Breast Cancer
Breast cancer (BC), the most common type of cancer, is the second leading cause of
cancer death in women in the United States (US). It is estimated that approximately 232,670
new cases of invasive BC, and about 62,570 new cases of carcinoma in situ (CIS) will be
diagnosed, and 40,000 women will die from BC in the US in 2014 1. Based on Surveillance,
Epidemiology and End Results (SEER) statistics for 2005-2009, the overall incidence of BC
from 2005-2009 was 82.97 per 100,000 in women age below 65 years and was 421.30 per
100,000 in women age 65 and above 2. The overall mortality from BC from 2005-2009 was
11.15 per 100,000 in women below 65 years of age and was 98.64 per 100,000 in women age 65
and above 2.
Total Healthcare Costs in the Initial Phase of One Year after Breast Cancer Diagnosis
Due to rapid scientific and technological advances in the field of oncology and with
increased adoption and utilization of more expensive cancer treatments as the standards of care,
and due to an increasing aging population, the costs of cancer care is expected to increase
enormously in the future. Based on a recent study, the national costs of cancer care in 2010 was
estimated to be $124.6 billion, out of which female BC comprised the highest proportion of 13%
($16.5 billion), which may increase by 32% in 2020 3. In addition, BC had the highest
expenditures in the initial phase of care (one year after diagnosis) among all other cancers 3.
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From $16.5 billion, 37% of the BC costs were for the initial phase of care, 41% were for the
continuing phase of care and 22% were for the last year of life.
A descriptive review on the costs of cancer care in the US reported that studies vary
widely with regards to study settings, methodology, cost perspective, stage at diagnosis,
populations, measurements of costs, types of services included, time horizons, and databases 4.
Moreover, none of the studies included in the review followed any published standards of
reporting costs analyses and hence called for future studies to follow these standards 4. A
systematic review of costs associated with BC in the US reported that the lifetime per-patient
direct medical care cost estimates of BC ranged from $20,000 to $100,000 for a base cost year
from 1984 to 2003 5. Yet the authors of this review suggested that the majority of the studies
included in the review were outdated, and hence the findings of the study did not reflect the
changes in patterns of care due to technological advances and innovations in BC treatment 5.
Also, most of the studies included in the review focused on women with BC stages disease I or II
5

.
The costs to Medicare of BC care are substantially higher during the initial phase of care

due to surgery, radiation and adjuvant therapy 5-9. Despite the extensive cost to Medicare during
the initial phase of care, there is inadequate information on costs incurred by types of specific
services, and average costs by stage at diagnosis, type of treatment, and number of comorbidities,
and the factors associated with higher costs of BC care. Recent studies on costs of cancer care in
the initial phase of care for elderly BC patients in the US have been based on old data (2003),
from fewer cancer registries, or for fewer disease stages 3,6,7,10. In addition, the average costs by
type of specific services, stage at diagnosis, type of initial treatment, and comorbidities have not
been reported 7,10. One study which determined the initial phase of care costs for Medicare
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beneficiaries in Virginia reported lower costs associated with BC care as compared to that from
the SEER-Medicare data, and that comorbidity, hospital stay, and type of treatment were
significant contributors of costs due to BC 11. However, there is limited information available
about the costs associated with BC care from rural settings and from non-SEER states. The costs
estimates from the previous studies may not be representative of Medicare reimbursements for
other geographic areas and across other populations in the US.
The population in WV is predominantly white and a considerable proportion reside in
rural areas. WV also has high poverty rates, low levels of education, aging population, high rates
of chronic diseases, and poor health behaviors 12-15. With lower incidence of BC among WV
women age 65 and older (372.8 per 100,000 vs. 410.6 per 100,000) but higher mortality (110.4
per 100,000 vs. 98.6 per 100,000) 16,17 than national estimates, and with higher rates of advanced
and unstaged BC in these women 18-22, it is likely that costs of BC care during the initial phase of
care may be higher. These findings will help to determine the extent to which costs are higher in
rural, underserved states such as WV with increasing median age.
Thus, the purpose of the study is to determine the average costs in the initial phase of care
among WV-Medicare fee-for-service (FFS) women beneficiaries and compare it with national
estimates derived from SEER-Medicare data, and to determine the factors associated with higher
costs in WV-Medicare women and compare it with the national estimates, after controlling for
predisposing factors (age, race), enabling factors (median household income, education level),
need-related factors (stage at diagnosis, grade of tumor, estrogen-receptor (ER) status, cooccurring physical and mental chronic conditions), healthcare use factors (number of primary
care physicians (PCP) visits in the year prior to BC diagnosis, type of initial cancer-related
treatment, inpatient stay) and external healthcare environmental factors (location of residence
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and number of hospitals offering oncology services in the area of residence). The post hoc
objective of the study is to utilize linear decomposition technique 23,24 to determine the
magnitude of differences in the average costs in the initial phase of care between WV-Medicare
and the SEER-Medicare, and to understand extent to which the predisposing, enabling, need,
healthcare use, and external healthcare environmental factors explain the differences in the
average costs between WV-Medicare and the SEER-Medicare cohorts.
METHODS
Data Source
West Virginia Cancer Registry-Medicare-Area Resource File linked dataset
The West Virginia Cancer Registry (WVCR) was established by the West Virginia
Department of Health and Human Resources in 1993 and it is a state-level cancer registry which
provides information on cancer incidence and mortality in West Virginia (WV) 25. The WVCR
collects and provides data on primary site of cancer, tumor grade, date and stage of diagnosis,
date and cause of mortality, and demographics such as age, gender, race, and also zip code (for
location of residence). The de-identified linked WVCR-Medicare dataset was developed at West
Virginia University (WVU) in full compliance with the WVU Institutional Review Board and
HIPPA requirements 26. The WVCR file served as the case source file from which the
information about individuals aged ≥ 65 years and diagnosed with cancer between the January 1,
2002 and December 31, 2007 was obtained. The Social security numbers (SSN) for these
individuals were provided to the CMS by the WVCR, using which the CMS identified the
corresponding Health Insurance Claim (HIC) number. A “crosswalk” file created using the HIC
allowed for linkage across the WVCR and the Medicare for extracting information on these
individuals as Medicare beneficiaries. Individuals with a missing SSN were excluded from the
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linkage. The Area Resource File (ARF) was linked to the WVCR-Medicare dataset using the
state and county FIPS codes for each beneficiary to extract the county level information on the
availability of healthcare facilities, healthcare providers, and socioeconomic characteristics of the
region’s population.
SEER-Medicare-Area Resource File linked dataset
The SEER-Medicare linked dataset provides population-based information on cancerrelated epidemiologic and health services research. The SEER-Medicare program collects
information on newly diagnosed cases of cancer from 17 population-based tumor registries
which collect information from several sources including hospitals, outpatient clinics,
laboratories, private practitioners, hospices, autopsy reports and death certificates. The SEERMedicare data represents approximately 26% of the US population. It is in the form of a
customized file known as the Patient Entitlement and Diagnosis Summary File (PEDSF) which
contains one record per person for individuals in the SEER database who have been matched
with Medicare enrollment records. It provides diagnostic information for up to 10 diagnosed
cancer cases (including date of cancer diagnosis, cancer sub-site, cancer stage at diagnosis, tumor
size, histology, grade), and information on the first course of cancer related treatment (surgery
and radiation provided in the first 4 months after diagnosis) for each individual. The PEDSF
additionally includes information on the median household income and education level for each
individual based on their census tract and zip code data.
The Medicare files that are a part of the SEER-Medicare linked dataset provide
information about any health care utilized in the inpatient, outpatient, physician, home health,
and hospice care by individuals age 65 and above who are enrolled in and are covered under the
Medicare program. All Medicare files include specific dates of service and codes for specific
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diagnosis and procedures using the International Classification of Disease, Ninth Edition (ICD-9)
codes or Common Procedure Terminology codes. The linkage of the SEER data with the
Medicare data, and formation of the SEER case number involves matching individuals across the
two files using an algorithm based on a match of SSN, name, sex, and date of birth. The linkage
process is described elsewhere 27. The Area Resource File (ARF) was linked to the SEERMedicare dataset using the state and county Federal Information Processing Standards (FIPS)
code for each beneficiary to get the county level information on the availability of healthcare
facilities and healthcare providers.
Study Design
This study utilized a retrospective observational cohort design to assess healthcare costs
during initial phase of care in Medicare FFS beneficiaries diagnosed with BC.
Study Cohorts
The two study cohorts comprised of women from WVCR-Medicare-ARF linked dataset
and SEER-Medicare-ARF linked dataset, age 66 and above at the first primary diagnosis of
incident BC between January 1, 2003 to December 31, 2006. These women were required to be
continuously enrolled in Medicare parts A and B at least 12 months prior to the BC diagnosis to
identify chronic conditions to measure comorbidity and till the follow up period of 12 months
after BC diagnosis to determine average total costs, and not enrolled in health maintenance
organizations (HMOs) at any time during this period. Women with a previous cancer diagnosis,
having an unknown or missing BC stage information, and who were diagnosed via death
certificate or autopsy were excluded from the study. Also women who died during the first 12
months after BC diagnosis were excluded from the study as these women may have dramatically
higher total average costs which may affect the estimates 9,11. Each beneficiary was followed for
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up to 12 months after BC diagnosis, to determine healthcare costs during the initial phase of care.
BC diagnosis codes were based on the primary site and International Classification of Diseases,
9th edition Clinical Modification (ICD-9-CM) codes 174.xx, 233.0x, 238.3x, and 239.3x.
The WVCR-Medicare-ARF linked dataset identified 2,814 women diagnosed with BC
from January 1, 2003 to December 31, 2006. The following women were excluded from the
final study cohort: 152 women who were below 66 years at diagnosis, 13 women who died
during the first 12 months after BC diagnosis, 526 women with any previous cancer diagnosis,
24 women who were diagnosed with BC during death or autopsy, 245 women with unknown or
missing BC stage, 234 women who were not continuously enrolled in Medicare parts A and B in
the 12 months before and 12 months after diagnosis, and 232 women who were members of a
HMO at any time during the study period. From the remaining 1,388 women, only 1 woman
(0.07%) had zero total expenditure in the initial period after BC diagnosis and hence was
removed from the analyses. Thus, a sample of 1,387 women was included in the final analyses.
The SEER-Medicare-ARF linked dataset had 112,719 women diagnosed with BC from
January 1, 2003 to December 31, 2006. The following women were excluded from the final
study cohort: 44,869 women who were below 66 years at diagnosis, 6,137 women who died
during the first 12 months after BC diagnosis, 3,123 women with any previous cancer diagnosis,
2 women who were diagnosed with BC during death or autopsy, 1,299 women with unknown or
missing BC stage, 3,292 women who were not continuously enrolled in Medicare parts A and B
in the 12 months before and 12 months after diagnosis, and 14,296 women who were members
of a HMO at any time during the study period. From the remaining 39,701 women, 176 women
(0.44%) had zero total costs in the initial phase of care and hence were removed from the
analyses. Thus, a sample of 39,525 women was included in the final analyses.

102

Measures
Cost Estimates: Costs of care in the initial phase of care were separately calculated for both the
study cohorts. All Medicare files including Inpatient (Medicare Analysis and Procedure),
Hospital Outpatient, Carrier/NCH, Hospice, Skilled Nursing Facility, Home Health Agency, and
Durable Medical Equipment, were used to estimate average direct medical costs in the initial
phase of care. In addition to total direct medical costs of care, average direct medical costs
within the categories of care such as inpatient services, outpatient services, physician services,
and other services (costs related to durable medical equipment, hospice care and home health
agency) were determined for both the study cohorts. The prescription drug costs were not
included in the analysis as data pertaining to prescription drugs was not available for the years of
the study.
The initial phase of care was defined as the year following BC diagnosis, based on the
following reasons cited by previous studies: initial course of treatment including adjuvant
therapy to be completed within one year of diagnosis, initial phase of care is also based on the
consensus from a group of clinical oncologists, and it could be used for comparison purposes
with previous literature 6,8,9,11,28.
Defining direct medical costs: Direct medical costs were defined as the amount reimbursed by
Medicare. Reimbursement rather than charges has been used as a proxy for medical care costs in
previous cost studies 8-10. Moreover, charges reflect price setting rather than resource
consumption and hence are not necessarily related to the cost of providing services 29.
Reimbursements are actual payments derived from reimbursement formulas which reflect the
average resource utilization for each healthcare service 29. Apart from calculating average total
direct medical costs, costs by type of specific services such as inpatient services, outpatient
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services, physician services, and other services were also calculated separately for both the study
cohorts to identify which Medicare component contributes substantially to the average total costs
of care. To account for variation in the costs of medical care services over time, consumer price
indices (CPI) for medical care services were utilized to convert costs to 2007 US dollars 30 and
hence all the costs are reported in 2007 US dollars. The Medicare reimbursement formulae for
all the services already include geographic factors which may affect geographic variations in the
costs, and hence the costs were not adjusted for any geographic variations.
Independent Variables: To identify the factors associated with healthcare costs in elderly
Medicare FFS with first primary incident BC, the Andersen behavioral healthcare services
utilization model was utilized 31,32. Based on this model, the independent variables were grouped
into predisposing factors, enabling factors, need-related factors, healthcare use factors and
external healthcare environmental factors (Figure 4.1).
Predisposing factors comprised of age at BC diagnosis (66-69, 70-74, 75-79, 80 and
older), and race (white, other), while enabling factors consisted of census tract median household
income (=<$35,000; >$35,000), and census tract percentage of people age >= 25 years with at
least 4 years of college education (<15%, >=15%). Since person-level information on household
income and education level are not available with both the SEER-Medicare and WV-Medicare
cohorts, census tract information for these two variables were used in this study. Need-related
factors included clinical factors such as stage at diagnosis (insitu, local, regional, distant), grade
of tumor (well-differentiated, moderately differentiated, poorly differentiated,
undifferentiated/unknown), estrogen-receptor status (positive, negative, borderline/unknown),
comorbidity scores and mental conditions (depression and/or anxiety) derived from co-occurring
chronic conditions during the twelve months before BC diagnosis identified from the Medicare
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files using the ICD-9-CM diagnosis codes. BC stage at diagnosis was determined according to
the SEER Summary staging system which uses all information available in the medical record.
It is a combination of the most precise clinical and pathological documentation of the extent of
disease 33. Comorbidity scores were calculated using Charlson comorbidity index with macros
provided by the National Cancer Institute 34-36 and were categorized as 0 (no comorbidity), 1, 2+.
Mental conditions included depression and/or anxiety and was dichotomized as presence or
absence of a mental condition. Factors associated with healthcare use were the number of PCP
visits in the 12 months prior to the BC diagnosis, type of initial treatment in the year subsequent
to BC diagnosis, and inpatient use. Similar to previous research, PCP visits were derived from
the National Claims History (NCH) files using the Medicare provider specialty field found in
NCH claims and the PCP included those in general practice (01), family practice (08), internal
medicine (11), geriatric medicine (38), and multi-specialty group practice (70) 37. The PCP visits
were categorized into two groups (high or low) based on the median value. Type of initial
treatment was categorized as definitive surgery only, non-surgical treatment (chemotherapy or
radiation therapy or both), definitive surgery plus non-surgical therapy, and no treatment.
Claims related to surgical procedures, chemotherapy, radiation therapy were identified from the
appropriate Medicare files using a combination of ICD-9-CM diagnosis and procedure codes,
CPT codes, HCPCS codes and revenue center codes. Inpatient use during the 12 months after
BC diagnosis was derived from the inpatient claims file and was dichotomized as presence or
absence of inpatient use. External healthcare environmental factors included location of
residence based on US Department of Agriculture rural-urban continuum codes (metro, nonmetro) and ARF-derived number of hospitals offering oncology-related services in the area of
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residence. The hospitals offering oncology-related services were categorized into two groups
(high or low) based on the median value.
Statistical Analyses
Descriptive statistics and chi-square statistics were used to describe the characteristics
and the significant differences in characteristics between the two study cohorts. CPI adjusted
average total direct medical costs during the initial period after BC diagnosis and average total
costs by types of specific services were estimated for both the study populations and were
statistically compared using t-tests and ratio-of-means. Ratio-of-means is obtained by dividing
average total costs of WV-Medicare cohort by average total costs of SEER-Medicare cohort. In
addition, average total costs by type of specific services among users of the respective services
were determined and reported. Adjusted average total direct medical costs were estimated for
clinically relevant variables such as stage at BC diagnosis, type of initial treatment and
comorbidity scores for both the study populations and their ratio-of-means were reported. Data
on adjusted average total costs and average costs by types of specific services for both WVMedicare and SEER-Medicare cohorts were positively skewed and with high kurtosis (>3).
Hence transformation of these costs data was required. Breusch-Pagan/Cook-Weisberg test and
simplified White test were performed to check for heteroscedasticity and kurtosis of log-scale
residuals in the costs data 38. Due to presence of distributional problems such as skewness,
kurtosis of log-scale residuals and heteroscedasticity, Park tests 39 were conducted for total costs,
and for costs by types of specific service for both the study populations to determine the most
appropriate model which may produce the most precise estimates for the costs data. The results
of the Park tests suggested that Generalized Linear Model (GLM) with log link function and
gamma distribution was the most appropriate regression to model costs in this study.
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GLM regressions with log transformation for adjusted total costs and gamma distribution
as the link function were conducted separately for both the study populations to determine the
predictors of total healthcare costs incurred during the initial period after BC diagnosis in elderly
women, after controlling for all the independent variables. GLM regressions were also
conducted on total, inpatient, outpatient, and physician services costs after controlling for setting
(WV-Medicare vs. SEER-Medicare) and other independent variables, to determine the
significant differences between total costs and costs by services between WV-Medicare and
SEER-Medicare cohorts. The independent variables, predisposing factors, enabling factors,
need-related factors, factors affecting healthcare use and external environmental healthcare
access factors were entered in sequential blocks in the regression models. Model 1 included only
‘type of setting (WV-Medicare vs SEER-Medicare)’ as an independent variable. Model 2 added
predisposing and enabling factors in addition to setting variable. Model 3 added need-related
factors and factors affecting healthcare use in addition to the variables specified in Model 2.
Model 4 included external healthcare environmental factors in addition to the variables specified
in Model 3. From the GLM regressions, the parameter estimates (beta coefficients), betas
transformed into corresponding average costs, and standard errors were examined. The findings
that were significant with p-values less than or equal to 0.05 levels were discussed. All analyses
were conducted within statistical analysis system software SAS 9.3 (SAS® version 9.3, SAS
Institute Inc., Cary, NC, USA) and Stata 13 (StataCorp.2013.Stata Statistical Software:Release
13.College Station,TX:StataCorp LP).
Blinder-Oaxaca Decomposition Technique
To determine the extent to which independent variables explained the differences in total
average costs in the initial year between WV-Medicare and SEER-Medicare, a post-regression
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linear decomposition technique was utilized 23,24. This technique helps in examining the
proportion of total setting difference (WV-Medicare vs SEER-Medicare) being explained by
different independent variables included in the model, and also in identifying how much of the
setting differences in total average costs were explained by these independent variables. The
decomposition method utilizes the parameter estimates (beta coefficients) from the regressions
and the means of independent variables to generate two components: ‘explained’ component
(also known as characteristics effect) which provides differences in the total costs due to
differences in observed characteristics between WV and SEER-Medicare, and ‘unexplained’
component (also known as coefficients effect) which provides differences in the total costs
between WV-Medicare and SEER-Medicare cohorts that could not be explained, either because
of differences in the regression parameter estimates between the two groups or differences in
unobservable or unmeasured independent variables (e.g. provider level, organizational level
variables) which were not captured and included in the model.
The explained portion was calculated by multiplying the differences in the average
characteristics between the WV-Medicare and SEER-Medicare cohorts with the pooled
regression weights. The pooled regression weights are the coefficients of the characteristics
from the regression model which used data from the WV-Medicare and SEER-Medicare cohorts.
The pooled regression model included type of setting as one of the independent variables in the
regression model.
RESULTS
Description of the Study Cohorts
Table 4.1 describes the WV-Medicare and SEER-Medicare cohorts age 66 and above,
diagnosed with the first primary incident BC in 2003-2006. Twenty-five percent of the women
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in the WV-Medicare cohort were age 80 and above as compared to 29% in SEER-Medicare
cohort. Majority of WV-Medicare cohort (97.6%) was white as compared to 89% from the
SEER-Medicare cohort. A higher proportion of WV-Medicare cohort had a household income
below $35,000 (91%), resided in areas with less than 15% population with some college
education (51%), had lower PCP visits (51%) and resided in areas with lower number of
hospitals with oncology services (60%). However, a majority of the SEER-Medicare cohort
resided in metro areas (84%), had household income above $35,000 (75%), resided in areas with
greater than 15% of population with some college education (70%), had lower PCP visits (54%),
and resided in areas with a lower number of hospitals with oncology services (55%).
Average Total Costs and Average Costs by Types of Services
Table 4.3 describes the CPI adjusted total average costs and average costs by types of
specific services during the initial phase of care for both the WV-Medicare and SEER-Medicare
cohorts, and also presents the ratio-of-means between the WV-Medicare and SEER-Medicare
cohorts. The average total costs for WV-Medicare cohort during initial phase of care was
$19,875 (SE=483), while the average total costs for those belonging to the SEER-Medicare
cohort was $22,881 (SE=100). The ratio-of-means was 0.87 and the total average costs for the
WV-Medicare cohort was significantly lower than that of the SEER-Medicare cohort. Total
average inpatient costs for WV-Medicare cohort $4,707 (SE=255) was also significantly lower
than the costs for SEER-Medicare cohort $5,254 (SE=59) with ratio-of-means of 0.90. The total
average outpatient costs for the WV-Medicare cohort and the SEER-Medicare cohort were
$5,767 (SE=237) and $5,806 (SE=34) respectively, with ratio-of-means 0.99. The total average
costs for physician services were significantly lower for the WV-Medicare cohort ($8,684,
SE=261) as compared to the SEER-Medicare cohort ($10,800, SE=57), with ratio-of-means of
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0.80. Also the total average costs for other services were significantly lower for the WVMedicare cohort ($716, SE=60) as compared to the SEER-Medicare cohort ($1,020, SE=16).
Among users of the specific services, total average inpatient costs were significantly
lower for the WV-Medicare cohort ($9,745) as compared to the SEER-Medicare cohort
($11,239), and ratio-of-means was 0.87. The total average costs among users of physician
services were also significantly lower for the WV-Medicare cohort ($8,684) as compared to the
SEER-Medicare cohort ($10,814) with a ratio-of-means of 0.80.
Average Total Costs for Clinically Important Variables
Table 4.4 describes the average total costs for clinically important variables such as stage
at diagnosis, type of initial treatment, and comorbidity score. Average total costs in the WVMedicare women with distant stage at BC diagnosis was $27,073 (SE=3,635) as compared to
$43,431 (SE=973) in the SEER-Medicare women with distant stage, and the ratio-of-means was
0.62. WV-Medicare cohort who had adjuvant therapy only as the initial treatment had average
total expenditures of $26,498 as compared to $33,786 for the SEER-Medicare cohort, with ratioof-means of 0.78. Average total costs were lower for the WV-Medicare cohort with 2 or more
comorbidities as compared to the SEER-Medicare cohort with two or comorbidities ($22,018 vs.
$27,593), with a ratio-of-means of 0.80.
Factors Associated with Average Total Costs
Table 4.5 summarizes the results from the separate GLM regression models on total
average costs during the initial phase of care in the WV-Medicare and the SEER-Medicare
cohorts. In the WV-Medicare cohort, women who had regional or distant stage of BC, who had
surgery with adjuvant therapy or who had adjuvant therapy only, who had inpatient visits, who
had two or more comorbidities, and who had either depression or anxiety had significantly
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higher total average costs. Also, WV-Medicare cohort who was age 75 or older had significantly
lower total average costs. In the SEER-Medicare cohort, women who resided in areas with
higher education, who were diagnosed at advanced stages of BC, who did not have a welldifferentiated tumor grade, who had negative ER tumor status, who had any kind of treatment in
form of surgery or adjuvant therapy, who had inpatient visits and PCP visits, and who had any
comorbidity had significantly higher total average costs. In addition, the SEER-Medicare cohort
who was age 70 or older, and who resided in non-metro areas had significantly lower total
average costs. The beta estimates and exponentiated average costs for all the independent
variables within each GLM regression are reported in Table 4.4.
Differences in Average Total Costs and Average Costs by Types of Services
Table 4.6 summarizes the results from the separate multivariate GLM regression models
on total average costs, average costs for types of specific services during the initial phase of care,
to identify any significant differences in these costs between WV-Medicare cohort and SEERMedicare cohort. As compared to the SEER-Medicare cohort, total average costs were
significantly lower for the WV-Medicare cohort. In Model 1 without adjusting for other
independent variables, the WV-Medicare cohort had lower total average healthcare costs as
compared to the SEER-Medicare cohort by $3,006. However, this difference shrunk to $549 in
Model 4 after adjusting for all the independent variables. The total average costs for inpatient
and physician services were also significantly lower for the WV-Medicare cohort as compared to
the average costs for these services for the SEER-Medicare cohort.
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Factors Explaining Lower Average Total Costs in the WV-Medicare Cohort Using BlinderOaxaca Linear Decomposition Analysis
Table 4.7 summarizes the results from the Blinder-Oaxaca linear decomposition analysis.
The total average costs for WV-Medicare cohort for the initial phase of care was $19,875 and
that for the SEER-Medicare cohort was $22,881, a difference of $3,006 in total average costs
between these two cohorts. Using the pooled weights, 15.82% of the difference in the total
average costs between the two cohorts was explained by the beneficiary characteristics.
Enabling resources (census tract income and education) contributed 6.85%, healthcare use (PCP
visits, type of initial treatment, inpatient use) contributed 7.53%, and external healthcare
environmental factors (location of residence, hospital visits) contributed 3.33% to the total
explained portion of 15.82%. Detailed examination of the decomposition results revealed that
the differences in the type of initial treatment explained 11.52% of the differences in the total
average costs between the two groups. This can be interpreted as follows: keeping all the other
characteristics same, if WV-Medicare cohort had the same course of initial treatment as the
SEER-Medicare cohort, then the WV-Medicare cohort would have had a lower total average
costs. A total of 84.14% of the differences in the total average costs in the initial phase of care
between WV-Medicare and SEER-Medicare cohorts remained unexplained.
Since only 16% of the differences between WV-Medicare and SEER-Medicare cohorts
were explained by the beneficiary characteristics discussed above, it was hypothesized that other
factors related to healthcare utilization such as number of radiation visits, number of
chemotherapy visits, and type of surgeon seen (general surgeon vs. oncology surgeon) may
explain a portion of lower total average costs in the WV-Medicare cohort. The post-hoc analyses
was conducted to evaluate significant differences between the study cohorts for the additional
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healthcare use factors such as number of radiation visits, number of chemotherapy visits and type
of surgeon seen by the Medicare beneficiaries and its results are reported in Table 4.2. A higher
proportion of the WV-Medicare cohort had no radiation visits as compared to the SEERMedicare cohort (51% vs. 47%). However, among those who had radiation visits, WV-Medicare
cohort had higher proportion of women with at least 10 radiation visits in the year following BC
diagnosis as compared to the SEER-Medicare cohort. There were no significant differences
between the two study cohorts for number of chemotherapy visits and type of surgeon seen in the
year following BC diagnosis. Another post-hoc Blinder-Oaxaca decomposition analyses was
also conducted to identify the extent to which the previously included independent variables and
the additional healthcare use factors explained the magnitude of differences in these study
cohorts. Using the pooled weights, only 11% of the difference in the total average costs between
the two cohorts was explained by the beneficiary characteristics (data not shown). Healthcare
use contributed 61%, enabling resources contributed 28% and external healthcare environmental
factors contributed 29% to the total explained portion (data not shown).
DISCUSSION
As the costs of BC constitute a substantial portion of the overall national costs of cancer
care and as these costs are likely to increase tremendously in the coming years 3, estimating the
BC costs and the costs by types of specific services is vital for the Medicare program to focus on
controlling these costs and setting priorities for the effective allocation of the resources.
Previous studies which estimated total average costs in the initial phase of care in BC patients
have been outdated and utilized data from SEER-Medicare registries only 3,6,7,10. This study is
first of its kind to identify costs by types of specific services and the factors associated with
higher costs in BC patients, from a non-SEER-Medicare and rural geographic region and
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compared it with the national estimates derived from SEER-Medicare data, and to examine the
which factors explained the differences in the average costs between the WV-Medicare and
SEER-Medicare cohorts. The study findings indicate that the two populations were statistically
different in terms of most of their characteristics. The total average costs, and the average costs
for inpatient services, physician services and other services in the initial phase of care in elderly
BC patients from WV-Medicare cohort was significantly lower than that for the SEER-Medicare
cohort. The total average costs, average costs for inpatient services and physician services were
13%, 13% and 20% higher, respectively, for SEER-Medicare cohort than for WV-Medicare
cohort as seen in Table 2. These findings did not change even after controlling for the
comprehensive list of covariates in the multivariate framework. A part of the lower costs in a
rural state such as WV as compared to the SEER-Medicare regions may be due to the differences
in the Medicare spending across various geographic regions in the US 40. In addition, average
costs by stage at diagnosis, type of initial treatment, and comorbidity scores were also lower for
the BC patients in WV than that for the SEER-Medicare elderly women.
In contrast to study by Warren et al., it was found that physician services was the major
contributor to the total average costs in the initial phase of care among the elderly WV-Medicare
and SEER-Medicare beneficiaries with BC 10, followed by outpatient costs and inpatient costs.
Average costs for physician services, inpatient services, and outpatient services were lower for
WV-Medicare cohort as compared to their national counterparts. Among users of specific
services, average costs due to inpatient services was the highest for both the groups, followed by
average costs due to physician services. However, these costs were lower for WV-Medicare
cohort as compared to their national counterparts. These findings are surprising given the fact
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that elderly WV women with BC have higher comorbidity burden and possibly greater
proportion of negative health-outcomes which may increase their total average costs.
In elderly WV women with BC, the factors associated with higher costs during the initial
phase of care were advanced stages of the cancer, surgery with adjuvant therapy or adjuvant
therapy only, any hospitalization, presence of two or more physical chronic conditions, and
presence of depression and/or anxiety. But older age was associated with lower average costs in
these women. These findings were consistent with those reported in the previous study on
Virginia population 11. These findings highlight the importance of encouraging women to utilize
preventive screenings to get them diagnosed at earlier stages of BC. In addition, the findings
also emphasize the importance of better co-management of physical and mental chronic
conditions in elderly women with BC, to lower overall costs to Medicare in a rural state such as
WV. Emerging healthcare delivery models such as ‘medical homes’ which emphasize carecoordination for management of the elderly Medicare beneficiaries with multiple chronic
conditions are a step in the right direction.
The differences in the total average costs for elderly women with BC were also examined
between the two cohorts in a multivariable setting. There were statistically significant difference
in the total average costs between the two groups after controlling for the predisposing, enabling,
need-related, healthcare use, and external healthcare environmental factors. The difference in
total average costs in the initial phase of care reduced from $3,006 to $549 after adjusting for all
the covariates.
The study also utilized the unique Blinder-Oaxaca linear decomposition technique to
examine the extent to which the differences in the various factors explained the difference in the
total average costs between the two cohorts. Enabling resources (household income and
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education), and healthcare use (PCP visits, type of initial treatment, inpatient use) primarily
explained the differences in the total average costs between the two populations. These findings
are consistent to the findings from previous studies which reported that the differences in
healthcare spending is largely explained by the differential treatment pattern owing to the supply
of physicians and hospital resources in the area, and also household income and education 41-44.
Hence, if both the study populations have similar household income and education, PCP visits,
initial treatment and inpatient use then the difference in the total average costs would shrink. A
noteworthy finding of this study is that around 84% of the difference in total average
expenditures between the two populations remained unexplained. It is plausible that some
portion of this difference may be due to unmeasured factors such as health status, severity of
comorbid conditions, body mass index, patient preferences and propensity to seek care. The
results of the post-hoc decomposition analyses after adding additional healthcare use factors such
as number of radiation visits, number of chemotherapy visits and type of surgeon seen by the
beneficiaries did not increase the ‘explained’ portion of the differences in the total average costs
between the two study cohorts. Hence, healthcare utilization may not be a contributing factor for
lower total average costs in the initial phase for the WV-Medicare cohort as compared to the
national averages.
Since the analyses of the costs for BC utilized the data from administrative claims, the
results of this study should be interpreted with caution. Any healthcare services obtained outside
of Medicare settings may not be captured, hence the costs may be underestimated. The costs of
adjuvant therapy with prescription drugs were not captured in the analyses as these costs were
not covered by Medicare prior to 2007. Also, indirect medical costs (e.g. cost due to lost
productivity), indirect non-medical costs, and out-of-pocket costs borne by patients were not
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included and hence the findings do not represent the total costs during the initial phase of care.
Certain patient characteristics such as annual household income, education level, access to total
of BC screening centers at patient level are not available in the cancer registries-Medicare linked
databases and hence census tract information for these variables have been utilized 45. Data on
some important variables such as health status, severity of comorbidities, and patient preferences
which may be important predictors of their cancer prognosis, or selection of type of treatment
were not available. Moreover, the findings of this study are generalizable to elderly BC patients
only covered by Medicare. Also the findings are not generalizable to other rural populations.
Costs may vary in a younger population due to differences in their age and insurance coverage.
CONCLUSION
The difference in the total average expenditures between the elderly beneficiaries with
BC from a rural state such as WV and their national counterparts narrowed but remained
significantly lower after multivariate adjustment, and is mainly driven by enabling factors and
healthcare use factors. Further research focusing on the incremental costs among elderly
beneficiaries with BC with combination of different comorbid conditions from rural areas is
suggested.
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Figure 4.1: The Andersen Behavioral Model for Health Care Utilization (Aim 3)
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Variables

Table 4.1
Description of the Study Cohorts
2003-2006
WV-Medicare
(N=1,387)
N

Age at Diagnosis
66-69
70-74
75-79
80,+
Race
White
Other
Location of Residence
Metro
Non-metro
Census Tract Household Income
LE $35,000
GT $35,000
Census Tract Education
LT 15% pop. with CE
GE 15% pop. with CE
Stage at Diagnosis
Insitu
Local
Regional
Distant
Grade of Tumor
Well Differentiated
Moderately Differentiated
Poorly Differentiated
Undifferentiated/Unknown
ER Status
Positive
Negative
Borderline/Unknown
Initial Treatment
Surgery Only
Surgery+Adjuvant Therapy
Adjuvant Therapy Only
No Treatment
Inpatient Use
Yes
No
Comorbidity
1-10 conditions
11 to 20 conditions
>20 conditions
Mental Condition
Yes
No

%

SEER-Medicare
(N=39,525)
N

%

275
384
379
349

19.8
27.7
27.3
25.2

8,799
9,868
9,331
11,527

22.3
25.0
23.6
29.2

1,354
33

97.6
2.4

34,992
4,533

88.5
11.5

761
626

54.9
45.1

32,989
6,536

83.5
16.5

1,267
120

91.4
8.6

9,764
29,761

24.7
75.3

703
684

50.7
49.3

12,056
27,469

30.5
69.5

209
866
273
39

15.1
62.5
19.7
2.7

6,610
22,738
8,985
1,192

16.7
57.5
22.7
3.0

325
472
306
284

23.4
34.0
22.1
20.5

8,459
15,524
9,969
5,573

21.4
39.3
25.2
14.1

627
126
634

45.2
9.1
45.7

27,260
5,412
6,853

69.0
13.7
17.3

560
765
16
46

40.4
55.2
1.2
3.3

14,478
23,494
581
972

36.6
59.4
1.5
2.5

681
706

49.1
50.9

18,621
20,904

47.1
52.9

715
416
256

51.6
30.0
18.4

23,039
10,629
5,857

58.3
26.9
14.8

134
1,253

9.7
90.3

2,411
6.1
37,114
93.9
(Continued)…

Sig
***

***

***

***

***

**

***

***

**

***

***
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Table 4.1
Description of the Study Cohorts
2003-2006
WV-Medicare
(N=1,387)

Variables

N

%

SEER-Medicare
(N=39,525)
N

%

PCP visits
High
Low
Total Hospitals with Oncology Services
High
Low

681
706

49.1
50.9

18,051
21,474

45.7
54.3

551
836

39.7
60.3

17,613
21,912

44.6
55.4

Sig
*

***

Note: Based on 1,387 elderly WV-Medicare women and 39,525 elderly SEER-Medicare women, age 66 and above diagnosed
with primary incident breast cancer from 2003 to 2006. WV, West Virginia; SEER, Surveillance, Epidemiology, and End
Results; ER, Estrogen-receptor; PCP, Primary Care Physicians; CE, College Education; pop., population; LE, Less than or equal
to; GT, Greater than; LT, Less than; GE, Greater than or equal to; Sig, Significance. Asterisks represent statistically significant
group differences based on χ2 tests: ***P<0.001; **001<=P<.01 ; *.01<=P<.05.

Variables

Table 4.2
Description of the Study Cohorts for Differences in the Healthcare Utilization
2003-2006
WV-Medicare
SEER-Medicare
(N=1,387)
(N=39,525)
N

Radiation Visits
No visit
Low visits (1-10)
High visits (10,+)
Chemotherapy Visits
No
Yes
Type of Surgeon Seen
No surgeon seen
General Surgeon
Oncology Surgeon
Both

%

N

%

700
201
486

50.5
14.5
35.0

18,475
11,563
9,487

46.7
29.3
24.0

1,084
303

78.2
21.8

30,545
8,980

77.3
22.7

31
355
73
928

2.2
25.6
5.3
66.9

752
9,287
2,320
27,166

1.9
23.5
5.9
68.7

Sig
***

Note: Based on 1,387 elderly WV-Medicare women and 39,525 elderly SEER-Medicare women, age 66 and above diagnosed
with primary incident breast cancer from 2003 to 2006. WV, West Virginia; SEER, Surveillance, Epidemiology, and End
Results; Sig, Significance. Asterisks represent statistically significant group differences based on χ2 tests: ***P<0.001;
**001<=P<.01 ; *.01<=P<.05.

124

Table 4.3
Average Total Healthcare Costs and Average Healthcare Costs by Type of Service
For the Study Cohorts
2003-2006
Among All Users
WV-Medicare (N=1,387)

Ratio-ofMeans

SEER-Medicare (N=39,525)

Average ($)

SE

%

Average ($)

SE

%

Total***

19,875

483

100%

22,881

100

100%

0.87

Inpatient*

4,707

255

24%

5,254

59

23%

0.90

Outpatient

5,767

237

29%

5,806

34

25%

0.99

Physician Services***

8,684

261

44%

10,800

57

47%

0.80

716

60

4%

1,020

16

4%

0.70

Other (HHA, HSP, DME)***

Among Users of Specific Services
WV-Medicare

SEER-Medicare

N

Average ($)

SE

N

Average ($)

SE

Inpatient*

670

9,745

454

18,479

11,239

111

Outpatient

1,372

5,830

239

38,531

5,956

34

Physician Services***

1,387

8,684

261

39,474

10,814

57

727

1,366

110

19,579

2,060

31

Other (HHA, HSP, DME)***

Note: Based on 1,387 elderly WV-Medicare women and 39,525 elderly SEER-Medicare women, age 66 and above diagnosed
with primary incident breast cancer from 2003 to 2006. WV, West Virginia; SEER, Surveillance, Epidemiology, and End
Results; CPI, Consumer Price Index; HHA, Home Health Agency; HSP, Hospice; DME, Durable Medical Equipment; SE,
Standard Error. Asterisks represent statistically significant group differences based on t-tests: ***P<0.001; **001<=P<.01 ;
*.01<=P<.05.
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Table 4.4
Average Total Healthcare Costs for Clinically Important Variables For the Study Cohorts
2003-2006
Among All Users

N

WV-Medicare
Average
costs ($)
SE

SEER-Medicare
Average
costs ($)

Ratio-of-Means

N

Insitu

209

13,148

871

6,610

14,872

169

0.88

Local

866

17,484

514

22,738

20,124

107

0.87

Regional

273

31,592

1,401

8,985

33,024

255

0.96

39

27,073

3,635

1,192

43,431

973

0.62

Surgery Only

560

12,306

593

14,478

15,119

137

0.81

Surgery+Adjuvant Therapy

SE

Stage at Diagnosis

Distant
Initial Treatment

765

25,664

660

23,494

27,774

129

0.92

Adjuvant Therapy Only

16

26,498

3,832

581

33,786

1,254

0.78

No Treatment

46

13,422

3,160

972

13,699

751

0.98

0

715

18,432

625

23,039

21,438

119

0.86

1

416

21,034

954

10,629

23,412

199

0.90

2,+

256

22,018

1,171

5,857

27,593

324

0.80

Comorbidity

Note: Based on 1,387 elderly WV-Medicare women and 39,525 elderly SEER-Medicare women, age 66 and above diagnosed
with primary incident breast cancer from 2003 to 2006. WV, West Virginia; SEER, Surveillance, Epidemiology, and End
Results; CPI, Consumer Price Index; SE, Standard Error.
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Table 4.5
Factors Associated with Average Total Healthcare Costs Separately for the Study Cohorts
Using Generalized Linear Model Regressions
2003-2006
Variables

WV-Medicare (N=1,387)
Average
Beta
costs ($)
SE

Sig

SEER-Medicare (N=39,525)
Average
Beta
costs ($)
SE
Sig

***

8.6028

5,447

0.0252

***

-0.0349

5,260

0.0086

***

8.6015

5,440

0.1342

70-74

-0.0666

5,089

0.0503

75-79

-0.1678

4,599

0.0507

***

-0.0836

5,010

0.0088

***

80,+

-0.1121

4,863

0.0538

*

-0.1376

4,747

0.0088

***

-0.0233

5,315

0.1120

-0.0096

5,395

0.0096

-0.0762

5,041

0.0440

-0.0814

5,021

0.0092

0.0208

5,554

0.0755

0.0150

5,529

0.0084

-0.0075

5,399

0.0477

0.0285

5,604

0.0076

***

Local

0.0940

5,976

0.0508

0.1625

6,408

0.0091

***

Regional

0.4257

8,327

0.0617

***

0.4081

8,192

0.0106

***

Distant

0.5909

9,822

0.1220

***

0.7389

11,404

0.0203

***

-0.0061

5,407

0.0462

0.0282

5,603

0.0080

***

0.0118

5,504

0.0538

0.0977

6,006

0.0093

***

-0.0504

5,172

0.0539

0.0365

5,649

0.0108

***

0.1061

6,049

0.0649

0.0976

6,005

0.0094

***

-0.0402

5,225

0.0369

0.0111

5,508

0.0087

Intercept (Baseline Costs)
Age at Diagnosis
66-69

Race
White
Other
Location of Residence
Metro
Non-metro

***

Census Tract Household Income
LE $35,000
GT $35,000
Census Tract Education
LT 15% pop. with CE
GE 15% pop. with CE
Stage at Diagnosis
Insitu

Grade of Tumor
Well Differentiated
Moderately Differentiated
Poorly Differentiated
Undifferentiated/Unknown
ER Status
Positive
Negative
Borderline/Unknown

(Continued)…
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Table 4.5
Factors Associated with Average Total Healthcare Costs Separately for the Study Cohorts
Using Generalized Linear Model Regressions
2003-2006
Variables

WV-Medicare (N=1,387)
Average
Beta
costs ($)
SE

Sig

SEER-Medicare (N=39,525)
Average
Beta
costs ($)
SE
Sig

Initial Treatment
Surgery Only

0.1165

6,112

0.1040

0.1843

6,549

0.0201

***

Surgery+Adjuvant Therapy

1.0199

15,084

0.1051

***

0.9223

13,699

0.0202

***

Adjuvant Therapy Only

0.7929

12,021

0.1867

***

0.7776

11,854

0.0317

***

0.7829

11,901

0.0370

***

0.7065

11,040

0.0065

***

1

0.0726

5,849

0.0395

0.0668

5,823

0.0070

***

2,+

0.1904

6,581

0.0478

***

0.2105

6,723

0.0090

***

0.2480

6,971

0.0581

***

0.0841

5,925

0.0125

***

0.0138

5,515

0.0353

0.0786

5,892

0.0062

***

0.0654

5,807

0.0498

0.0738

5,864

0.0066

***

No Treatment
Inpatient Use
Yes
No
Comorbidity
0

Mental Condition
Yes
No
PCP visits
High
Low
Total Hospitals with Oncology Services
High
Low

Note: Based on average costs in initial phase of care, in 1,387 elderly WV-Medicare women and 39,525 elderly SEER-Medicare
women, age 66 and above from 2003 to 2006 diagnosed with first primary incident breast cancer from 2003 to 2006. FFS, Feefor-service; WV, West Virginia; SEER, Surveillance, Epidemiology, and End Results; CPI, Consumer Price Index; SE, Standard
Error; ER, Estrogen-receptor; PCP, Primary Care Physicians; CE, College Education; pop., population; LE, Less than or equal to;
GT, Greater than; LT, Less than; GE, Greater than or equal to; Sig, Significance. Asterisks represent statistically significant
group differences based on Generalized Linear Model with gamma distribution and log link function: ***P<0.001;
**001<=P<.01 ; *.01<=P<.05.
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Table 4.6
Differences in Average Total Costs between the Study Cohorts
Using Generalized Linear Model Regressions
2003-2006

Beta

Model 1
Average
costs ($)

Model 2
Average
costs ($)
SE

SE

Sig

Beta

Intercept

10.0381

22,882

0.0039

***

10.1151

24,713

WV-Medicare

-0.1410

19,873

0.0210

***

-0.1107

9.3271

11,238

0.0065

***

-0.1436

9,735

0.0349

8.6922

5,956

0.0051

-0.0209

5,833

0.0275

9.2886

10,814

0.0042

-0.2191

8,686

0.0228

Model 3
Average
costs ($)
SE

Sig

Beta

0.0111

***

8.5944

5,401

22,124

0.0218

***

-0.1029

9.1568

9,479

0.0187

***

***

-0.0819

8,733

0.0361

***

8.7953

6,603

0.0145

0.0092

6,664

0.0284

***

9.4193

12,324

0.0116

***

-0.1406

10,708

0.0230

Model 4
Average
costs ($)
SE

Sig

Beta

Sig

0.0244

***

8.6060

5,464

0.0248

***

4,873

0.0170

***

-0.1059

4,915

0.0170

***

9.6841

16,060

0.4973

***

9.7625

17,370

0.4948

***

*

-0.0915

14,656

0.0353

**

-0.0917

15,848

0.0351

**

***

7.3029

1,485

0.0374

***

7.2181

1,364

0.0380

***

0.0508

1,562

0.0245

*

0.0328

1,409

0.0244

***

7.5664

1,932

0.0262

***

7.6349

2,069

0.0266

***

***

-0.1531

1,658

0.0183

***

-0.1377

1,803

0.0183

***

Total Costs

SEER-Medicare
Inpatient Costs
Intercept
WV-Medicare
SEER-Medicare
Outpatient Costs
Intercept
WV-Medicare
SEER-Medicare
Physician Services Costs
Intercept
WV-Medicare
SEER-Medicare
Note: Based on average costs in initial phase of care, in 1,387 elderly WV-Medicare women and 39,525 elderly SEER-Medicare women, age 66 and above from 2003 to 2006
diagnosed with first primary incident breast cancer from 2003 to 2006. WV, West Virginia; SEER, Surveillance, Epidemiology, and End Results; CPI, Consumer Price Index; SE,
Standard Error; Sig, Significance. Asterisks represent statistically significant group differences based on Generalized Linear Model with gamma distribution and log link function:
***P<0.001; **001<=P<.01 ; *.01<=P<.05.
Model 1 includes only WV-Medicare/SEER-Medicare groups and no other independent variables
Model 2 includes WV-Medicare/SEER-Medicare groups, and adjusts for predisposing (age, race) and enabling (census tract income and education) as independent variables
Model 3 includes WV-Medicare/SEER-Medicare groups, and adjusts for predisposing (age, race), enabling (census tract income and education), need-related (stage at diagnosis,
grade of tumor, estrogen receptor status, comorbidities, mental conditions) and healthcare use (Primary care physician visits, type of initial treatment, inpatient use) as independent
variables
Model 4 includes WV-Medicare/SEER-Medicare groups, and adjusts for the independent variables listed above in addition to external healthcare environmental factors (location of
residence, number of hospitals with oncology services)
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Table 4.7
Factors Explaining Lower Total Average Costs in WV-Medicare Cohort
Using Blinder-Oaxaca Linear Decomposition Analysis
2003-2006

Variables
Predisposing characteristics (Age, Race)
Enabling resources (Census tract Annual Household Income and
Education)
Need-Related Variables (Stage at Diagnosis, Grade of Tumor, ER
status, Comorbidity, Mental Conditions)
Healthcare Use (PCP visits, Type of Initial Treatment, Inpatient
use)
External Healthcare Environmental Factors (Location of Residence,
Number of Hospitals with Oncology Services)
Total Difference Explained
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Pooled
Weights
-0.40%

% Contribution to the
‘Explained’ Portion
-2.53%

6.85%

43.30%

-1.50%

-9.48%

7.53%

47.60%

3.33%

21.05%

15.82%

100.00%

CHAPTER 5
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CHAPTER 5
SUMMARY AND CONCLUSIONS
RATIONALE AND OBJECTIVES
Breast cancer (BC) is the most common cancer among women and is the second leading
cause of cancer death in women in the United States (US). Based on 2005-2009 Surveillance,
Epidemiology and End Results (SEER) statistics, 41% of the new BC cases and 57.4% of the BC
deaths occur in women age 65 and above 1. The overall incidence of BC in women below 65
years of age is 82.97 per 100,000 women and is 421.30 per 100,000 women in those above age
65 1. The overall mortality from BC is 11.15 per 100,000 women for those less than 65 years of
age and is 98.64 per 100,000 women in those above age 65 1. Besides, elderly women age 65
and above have a greater burden of BC as they are diagnosed at more advanced stages and with
larger tumors impacting their survival 2.
In a rural state such as WV which is medically underserved with rates of chronic disease
and poor health behaviors 3-6, rates of advanced and unstaged BC are high 7-11 owing to lower
mammography screening rates in women in this state 8-12. Also, WV have lower incidence of BC
(372.8 per 100,000 vs. 411.7 per 100,000) but higher BC-related mortality (110.4 per 100,000 vs.
98.6 per 100,000) as compared to the national estimates 13,14. These may be because of low
mammography screening rates 9-11,15, limited physical access to services, shortage of healthcare
professionals and services 16, and untimely BC care. These disparities also indicate that elderly
women diagnosed with BC in WV may have higher healthcare costs after cancer diagnosis.
There is no clear evidence about the beneficial effects of mammography screening in
elderly women age 65 and above due to lack of inclusion of these women in clinical trials 17 and
discrepancy about evidence-based guidelines for mammography screening in these women.
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Previous published studies which reported benefits of mammography screening on representation
of stage of BC in elderly women have been limited in terms of including women of certain age
groups only, utilizing data from fewer cancer registries, not capturing persistent mammography
utilization before BC diagnosis, and not distinguishing screening from diagnostic mammography
claims which is an inherent issue with Medicare claims data 18-21. Moreover, very limited
information is available about the association between mammography screening and stage of
disease in elderly Medicare beneficiaries with BC from a rural setting and from non-SEERMedicare states.
Although timely care in BC patients is highly crucial, the US-based guidelines have not
yet defined an appropriate time frame for diagnosis and treatment. Previous published studies on
timeliness of BC care 22-30 have no consensus in regards to an appropriate time for diagnosis and
treatment. Also none of these studies have followed any published opinion-based guidelines to
appropriately define timely diagnosis and treatment. With lower incidence of BC but higher BCrelated mortality in elderly women in WV as compared to national estimates, it is highly likely
that timeliness of BC care may be one of the important contributors to these disparities.
Female BC comprises the highest proportion of national cancer care costs which is
expected to increase by 32% in 2020 31. In addition, BC has the highest costs in the initial phase
of care (one year after diagnosis) among all the cancers 31. A systematic review on BC costs in
the US suggested that majority of the studies included in the review were outdated and/or
focused on women with selected stages only 32. Few recent studies on costs have utilized data
only till 2003 and from fewer cancer registries 31,33-35. Moreover, very limited information is
available about BC costs from a rural setting and from non-SEER states.
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To address these gaps in the literature and to identify the factors associated with higher
BC-mortality in the elderly WV women, a series of retrospective observational cohort studies
were conducted using data from the elderly fee-for-service (FFS) Medicare beneficiaries with
first incident primary BC from the West Virginia Cancer Registry (WVCR)-Medicare linked
dataset and the results were compared with national estimates derived from the SEER-Medicare
linked dataset. In study one, the proportion of Medicare FFS beneficiaries in WV with incident
BC persistent with mammography screening and the association between persistence with
mammography screening and stage at BC diagnosis in a multivariate framework was determined
and compared with the national estimates derived from the SEER-Medicare dataset. In study
two, timeliness of BC care in terms of timely diagnosis and timely treatment based on published
opinion-based guidelines, factors associated with timeliness and the effect of timely care on the
probability of being alive were examined in elderly WV women with BC and compared with the
national estimates derived from the SEER-Medicare dataset. In study three, total average
healthcare utilization and costs in the initial period of one year after BC diagnosis and average
utilization and costs by types of services and the factors associated with higher healthcare costs
in initial period were evaluated in elderly WV women and these estimates were compared with
the national estimates derived from the SEER-Medicare dataset.
SUMMARY OF FINDINGS
Overall, the study findings indicated that the elderly FFS Medicare beneficiaries with
first primary incident BC from WV were statistically different from the nationally representative
population from SEER-Medicare. The WV-Medicare study cohort was relatively younger,
predominantly white, lived in non-metro areas, with lower median household income and mainly
belonged to the areas with lower percentage of people with college education as compared to the
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SEER-Medicare cohort. In addition, the WV-Medicare cohort was mostly diagnosed at local
stage of BC, had higher primary care physicians (PCP) visits, and had two or more comorbid
chronic conditions.
Persistence with Mammography Screening and Stage at Diagnosis among Elderly Women
Diagnosed with Breast Cancer
In the retrospective observational cohort study, 51% of women in WV-Medicare cohort
were persistent with mammography screening as compared to 45.4% in the SEER-Medicare
cohort. In the WV-Medicare cohort, of those not persistent with mammography screening, 31%
were diagnosed with late stage BC while among those who were persistent with mammography
screening, only 12% were diagnosed with late stage BC. However, in the SEER-Medicare
cohort, of those not persistent with mammography screening, 39% were diagnosed with late
stage BC while 17% were diagnosed with late stage BC among those who were persistent with
mammography screening. In the multivariate framework for the WV study cohort, persistence
with mammography screening was significantly associated with early stage BC. While for the
SEER-Medicare cohort, persistence with mammography screening, higher household income
and higher PCP visits were significantly associated with earlier stage at BC diagnosis. This
study also showed that elderly FFS Medicare beneficiaries with BC in WV were equally likely to
be diagnosed at an early stage of BC as compared to their national counterparts from SEERMedicare after controlling for persistence with mammography screening. The study findings
contradict reports of lower mammography utilization in WV 8,9,12,36 as the contributor of late
stage BC leading to higher BC-related mortality. This also indicates that there may be other
factors such as poor health status, family history of BC, BRCA gene mutation, untimely or
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inappropriate care that may be responsible for higher rates of late stage BC in elderly women in
WV, which affect their survival.
Timeliness of Care among Elderly Women Diagnosed with Breast Cancer
In this retrospective observational cohort study, the median days from initial consultation
for abnormality to BC diagnosis was 26 (Interquartile Range (IQR)=12-50 days) for the WVMedicare cohort as compared to 20 (IQR=8 to 41 days) for the SEER-Medicare cohort. The
overall median days from BC diagnosis to any BC treatment was 8 (IQR=0-28 days) for the WVMedicare cohort as compared to 15 (IQR=0-29 days) for the SEER-Medicare cohort.
Approximately, only 63% of women in the WV-Medicare cohort received timely diagnosis of
BC (i.e. consistent with the published opinion-based EUSOMA recommendations) as compared
to 71% of the SEER-Medicare cohort. Also, 76% of the WV-Medicare cohort received timely
BC treatment (i.e. consistent with the published opinion-based NICE recommendations) as
compared to 73% from the SEER-Medicare cohort. For the WV-Medicare cohort, census tract
household income above $35,000 and tumor size > 3 cm was significantly associated with timely
diagnosis of BC; however, no factors were significantly associated with timely treatment of BC.
In addition, the WV-Medicare cohort was significantly less likely to receive timely diagnosis of
BC but it was equally likely as the SEER-Medicare cohort to receive timely treatment for BC.
Furthermore, the WV-Medicare cohort was significantly more likely to be alive at the follow-up
period of three years as compared to the SEER-Medicare cohort. It is possible that other factors
such as WV women’s social and cultural barriers including fear, sense of fatalism, knowledge
and beliefs, perceived risk, physicians’ characteristics, and health system factors 24,37-43 which are
not measured in this study may be contributing to the higher BC-mortality rate among WV
women. The higher probability of being alive at the end of follow-up period for WV-Medicare
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cohort compared to the SEER-Medicare cohort indicates that a three years follow-up period may
not produce sufficient robust statistical estimates as compared to longer follow up period to make
any conclusions in this regards due to higher five-year survival in women with BC.
Total Healthcare Costs of Breast Cancer in the Initial Phase (12-months) After Diagnosis
In this retrospective observational cohort study, the average total healthcare costs, the
average total inpatient costs, and the average total costs for physician services in the initial phase
of one year following BC diagnosis for the WV-Medicare cohort was significantly lower than
that for the SEER-Medicare cohort. In the multivariate framework, these differences shrunk but
continued to remain significant. In the WV-Medicare cohort, women who had regional or distant
stage of BC, who had surgery with adjuvant therapy or who had adjuvant therapy only, who had
inpatient visits, who had two or more comorbidities, and who had either depression or anxiety
had significantly higher total average costs. Also, in the WV-Medicare cohort women who were
of age 75 or older had significantly lower total average costs. In the Blinder-Oaxaca
decomposition analyses, only 15.82% of the difference in the total average costs between the
WV-Medicare and SEER-Medicare cohorts was explained by the beneficiary characteristics.
Enabling resources (census tract income and education) contributed 6.85%, healthcare use (PCP
visits, type of initial treatment, inpatient use) contributed 7.53%, and external healthcare
environmental factors (location of residence, hospital visits) contributed 3.33% to the total
explained portion of 15.82%. A total of 84.14% of the differences in the total average costs in
the initial phase of care between WV-Medicare and SEER-Medicare cohorts remained
unexplained. The study findings indicate that a portion of the lower costs in a rural state such as
WV as compared to the SEER-Medicare regions may be due to the differences in the Medicare
spending across various geographic regions in the US 44. Also, these findings are surprising
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given the higher comorbidity burden which should increase the total average costs in the initial
phase following BC diagnosis. Furthermore, the study findings highlight the importance of
encouraging elderly WV women to utilize preventive screenings to get BC diagnosis at earlier
stages. These also emphasize the importance of better co-management of physical and mental
chronic conditions in this rural and elderly population, to lower overall costs to Medicare in a
rural WV state. The findings from the Blinder-Oaxaca decomposition analyses indicate that a
larger portion of ‘unexplained’ differences may be due to unmeasured factors such as health
status, severity of comorbid conditions, BMI, patient preferences and propensity to seek care.
CONCLUSION
This project laid the foundation or larger studies aimed at reducing and eliminating BC
disparities in a rural and geographically challenged state such as WV whose population is aging
and has lower socio-economic status. Given that the elderly WV women had lower incidence of
BC but higher BC-related mortality as compared to the national estimates 13,14, various factors
such as mammography screening, timeliness of care, appropriateness of care, physical access to
healthcare services and healthcare professionals need to be studied to determine if these factors
are the contributors to these disparities. In this project, the association between persistence with
mammography screening and stage at BC diagnosis, timeliness of BC care based on published
opinion-based recommendations, and total average costs in the initial phase were evaluated and
estimated to identify if these factors contributed to the higher BC-related mortality in the rural
state and if these rural women bore higher costs in the initial phase. The study findings directed
that only timely diagnosis of BC as per published recommendations is an issue in rural WV,
however the chances of survival were better in this population as compared to the estimates from
their national counterparts. Various unmeasured factors such as health status, BMI, severity of
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comorbid conditions, patient preferences, social and cultural barriers to care and several
physician related and health system factors may be contributing to higher BC-related mortality in
elderly WV women.
FUTURE RESEARCH
Studies investigating the effect of long term persistence with mammography screening
(e.g. 10-years) on stage at BC diagnosis after controlling for important covariates such as health
status, BMI, patient preferences, and beliefs knowledge about mammography screening that may
generate a clear picture about the beneficial effects of mammography screening in this rural and
elderly population are suggested. In addition, studies which controls for various factors such as
fear, sense of fatalism, knowledge and beliefs about BC, perceived risk, physicians’
characteristics, and health system factors which may affect timely BC care are advocated.
Furthermore, studies evaluating the effect of timely BC care on survival in elderly women should
include longer follow-up period of at least five to ten years to produce accurate conclusions
about this association. Future research focusing on the incremental costs due to presence of
various co-occurring chronic conditions among elderly population with BC from rural areas is
also recommended. Moreover, studies estimating indirect medical costs, indirect non-medical
costs, out-of-pocket costs and caregiver burden in elderly women with BC in a rural setting are
suggested.
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